New drug targets to prevent death due to stroke: a review based on results of protein-protein interaction network, enrichment and annotation analyses.

Michael Maes¹,²,³, Nikita G. Nikiforov⁴,⁵,⁶, Kitiporn Plaimas⁷, Apichat Suratanee⁸, Edna Maria Vissoci Reiche⁹

¹ Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; dr.michaelmaes@hotmail.com
² Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria.
³ IMPACT Strategic Research Center, Deakin University, Geelong, Australia.
⁴ Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia; nikiforov.mipt@gmail.com
⁵ National Medical Research Center of Cardiology, Institute of Experimental Cardiology, Moscow, Russia.
⁶ Institute of Gene Biology, Moscow, Russia.
⁷ Advanced Virtual and Intelligent Computing (AVIC) Center, Department of Mathematics and Computer Science, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand; kplaimas@gmail.com
⁸ Department of Mathematics, Faculty of Applied Science, King Mongkut’s University of Technology North Bangkok, Bangkok 10800, Thailand; apichat.s@sci.kmutnb.ac.th.
⁹ Laboratory of Research in Applied Immunology, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil; reiche@sercomtel.com.br
Corresponding author:

Michael Maes, M.D., Ph.D.

IMPACT Strategic Research Center, Barwon Health,

Deakin University, Geelong, Vic,

Australia

dr.michaelmaes@hotmail.com

https://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao
Abstract
This study used established biomarkers of death due to ischemic stroke (IS) and performed network, enrichment, and annotation analysis. Protein-protein interaction (PPI) network analysis revealed that the backbone of the highly connective network of IS death consisted of IL6, ALB, TNF, SERPINE1, VWF, VCAM1, TGFB1, and SELE. Cluster analysis revealed immune and hemostasis subnetworks, which were strongly interconnected through the major switches ALB and VWF. Enrichment analysis revealed that the PPI immune subnetwork of death due to IS was highly associated with TLR2/4, TNF, JAK-STAT, NOD, IL10, IL13, IL4, and TGF-β1/SMAD pathways. The top biological and molecular functions and pathways enriched in the hemostasis network of death due IS were platelet degranulation and activation, the intrinsic pathway of fibrin clot formation, the urokinase-type plasminogen activator pathway, post-translational protein phosphorylation, integrin cell surface interactions, and the proteoglycan-integrin-extra cellular matrix complex (ECM). Regulation Explorer analysis of transcriptional factors shows: a) that NFKB1, RELA and SP1 were the major regulating actors of the PPI network; and b) hsa-mir-26-5p and hsa-16-5p were the major regulating microRNA actors. In conclusion, prevention of death due to IS should consider that current IS treatments may be improved by targeting VWF, VEGFA, proteoglycan-integrin-ECM complex, NFKB/RELA and SP1.

Word counts: 199

Keywords: stroke; inflammation; neuro-immune; cytokines; hemostasis; coagulation; protein-protein interactions
1. Introduction

Acute ischemic stroke (IS) is one of the major health problems worldwide which frequently causes severe functional disabilities and mortality [1,2]. IS risk factors comprise unmodifiable factors including age, sex and ethnicity, and modifiable factors including diabetes mellitus (DM), increased systolic blood pressure ($\geq 140$ mm Hg), increased body mass index (BMI) or body weight, heart diseases, atrial fibrillation, transient ischemic attack (TIA), metabolic syndrome, smoking, sedentary life style, alcohol dependence, genetics and nutritional factors [1-4]. IS is the consequence of blood vessel clots in the brain which interrupt blood flow and lead to lack of oxygen causing cellular damage and neuronal cell death with neurodegenerative processes [5]. When vessels are occluded, inflammatory mediators are locally generated and propagated throughout the brain and peripheral blood circulation leading to neuroinflammatory processes and a systemic immune-inflammatory response [6].

Apart from being a neurodegenerative and neuroinflammatory disorder, IS is also an atherothrombotic disease with activation of hemostasis, coagulation, fibrin clotting, and fibrinolysis cascades coupled with endothelial dysfunctions [7,8]. Thus, reduced levels of natural anticoagulants including protein C (PROC), protein S (PROS1), and antithrombin (SERPINC1), are not only associated with an increased risk of venous thrombosis, but also with the progression, outcome and prognosis of IS [8-12]. Major adhesion molecules, including vascular cellular adhesion molecule-1 (VCAM-1) and E-selectin (endothelial-leukocyte adhesion molecule 1/SELE) facilitate migration of leukocytes towards inflammatory regions and play a role in the outcome of IS [8].

The mean carotid intima media thickness (cIMT), as measured through carotid Doppler ultrasonography, is a marker of severity of atherosclerosis and is associated with the severity and outcome of IS [8,13]. The baseline IS severity and IS-induced disabilities may be assessed using
the National Institutes of Health Stroke Scale (NIHSS) [14] and the modified Rankin score (mRS) [15], respectively. Both scales are also useful to predict the functional outcome of IS either short-term (three months) or long term (one year) outcome [16-19].

IS is the second leading cause of mortality and around one-third of IS patients may die within the first few months after the ischemic event [20,21]. The cumulative risk for death at 28 days after IS (labeled as “28 days fatality” or “deaths from stroke”) is around 28% and the risks at 1 and 5 year are 41% and 60%, respectively [22-24]. In nonfatal IS, the risk of death within the first year after the index stroke is 5 times higher than in a non-stroke population. In patients with initially nonfatal IS, the subsequent increased mortality rate is ascribed to vascular diseases, especially cerebrovascular and ischemic heart disease, neoplasms, infectious disease, diseases of the respiratory system, accidents and suicide [23].

Risk factors of increased mortality due to IS comprise increased age, increased cIMT scores, previous stroke and TIA, diabetes mellitus, heart disease, atrial fibrillation, increased baseline NIHSS and mRS scores, fever, and size of lesion [8,13,25-29]. Post IS death (three months and one year after admission) is predicted (as compared with surviving IS patients) by different baseline blood-based biomarkers: 1) increased levels of glucose, but reduced levels of high-density lipoprotein (HDL)-cholesterol and 25-hydroxyvitamin D [25(OH)D]; 2) reduced levels of the natural anticoagulants PROC, PROS1, and SERPINC1, and increased levels of Von Willebrand Factor (VWF), fibrinogen (FBG), and Factor 8 (F8); 3) increased levels of immune-inflammatory factors including white blood cell counts (WBC), interleukin (IL)-6, IL-10, tumor necrosis factor (TNF)-α, high sensitivity C-reactive protein (hsCRP), and ferritin; and lowered levels of transforming growth factor (TGF)-β1 and albumin (ALB); and 4) increased levels of the adhesion molecules SELE and VCAM-1 [8]. In fact, in machine learning models, different
combinations of increased cIMT and NIHSS scores and those biomarkers yield the most accurate prediction of short and long-term mortality due to IS [(8,13)].

A review of the existing literature shows that a number of genes may increase risk of mortality due to IS, including SERPINE1 (serine protein inhibitor E1) or plasminogen activator inhibitor 1 (PAI-1), ITGB3 (integrin beta-3), MPG (DNA-3-methyladenine glycosylase), PROCR gene (soluble endothelial protein C receptor), HABP2 (Hyaluronan Binding Protein 2), COL3A1 (type III collagen), FBG, RETN (resistin), VKORC1 (Vitamin K epoxide reductase complex subunit 1), INADL (InaD-Like Protein, PALS1-Associated Tight Junction Protein), and FXIIIA Val34Leu genetic variant [30-40] Moreover, the micro-RNA (miR)-10a rs3809783 A>T (MIR10A) and miR-34b/c rs4938723 T>C genetic variant (MIR34B) and the long noncoding RNA (lncRNA) AL110200 are associated with increased mortality rates due to IS [41,42].

Although risk factor control, antithrombotic treatment, and revascularization have been widely applied in clinical practice, IS is still a main cause of death [43]. The state-of-the-art management of IS comprises treatments targeting stroke-induced neurological damage and restoring the blood flow to the brain including treatment with recombinant tissue plasminogen activator (tPA) IV [2]. Surgical decompression reduces risk of mortality, although in elderly patients, decompression may be accompanied by an increased risk of long-term dependency [44]. The Action Plan for Stroke in Europe [45] considers that considerable effort should be focused on neuro-immune, neuroprotective and vascular pathways.

Therefore, in the era of precision medicine, novel strategies for the prevention and treatment of IS are urgently needed [46]. Identifying disease susceptibility and outcome genes/variants by itself may not provide insights into the relevant pathophysiologic pathways. IS is an exceptionally complex disease with the interaction between genetic, epigenetic and
transcriptional factors and proteins as well. Most genetic and metabolic studies to date have focused on identifying and characterizing the individual genes or metabolic pathways that contribute to the IS susceptibility and outcome. While these approaches continue to be informative, many genes/proteins with small to modest effects often act in networks to influence susceptibility and the outcome to complex diseases, such as the IS. However, no studies today have identified the interactome, the possible subnetworks, the most influential genes (hubs or bottlenecks), and the pathways, biological functions and cellular components which characterize death due to IS.

Knowledge-based approaches, such as enrichment and annotation analysis, and network and pathway analysis may provide insights into how genes and proteins interact to influence disease susceptibility. Moreover, protein-protein interaction (PPI) analysis may disclose new drug targets to develop novel therapies that modulate pathways and transcriptional factors thereby reducing death due to IS. Hence, the present study was conducted to delineate the characteristics of the PPI network of death due to IS and to discover new putative drug targets in the pathways, cellular components, molecular patterns, and transcriptional factors enriched in the PPI networks of IS-associated mortality based on differentially expressed proteins (DEPs)/genes delineated in ours and other studies.

2. Results

2.1 DEP analysis

2.1.1 The DEP PPI network topography of death due to ischemic stroke

Figure 1 displays the first order protein network of death due to IS and it consists of 65 nodes with 806 edges which exceeds the expected number of edges (n=220) with a p-enrichment value of 1.0e-16. The average node degree of this network is 24.8 with an average local clustering
coefficient of 0.735. The network diameter = 3 and radius = 2, with a characteristic path length = 1.658, network density = 0.388 and heterogeneity = 0.445. The top-6 hubs were in descending order of importance: IL6 (degree=51), TNF (46), ALB (46), VCAM1 (38), IL10 (36) and VWF (35). The top-2 non-hub bottlenecks were: SELE (0.0298) and TGFB1 (0.0243). As such, the backbone of the network comprises 8 proteins, including IL6, TNF, ALB, VCAM-1, IL-10, VWF, SELE, and TGF-β1.

MCL cluster analysis with an inflation parameter of three showed two protein communalities (see Figure 1): a) a first cluster centered around immune DEPs and comprised TNF, IL6, IL10, VCAM1, ALB, CRP, SELE, TGFB1, and ferritin heavy chain 1 (FTH1); and b) a second cluster centered around hemostasis DEPs including VWF, PROS, PROC, SERPINC1, and F8. The major switches between these clusters were ALB and VWF. ALB, which belongs to cluster 1, is interconnected with all cluster 1 and cluster 2 seed genes at a > 0.7 confidence levels (except with FTH1=0.577), and shows interconnections at a confidence level > 0.9 with cluster 1 (TGF-β1, CRP, IL-6) and cluster 2 (PROC, VWF, PROS1, F8, FGB, SERPINC1) DEPs. VWF, which belongs to cluster 2, is interconnected with all cluster 1 and cluster 2 DEPs at a confidence level > 0.4 (except with FTH1), while VWF shows interconnections at a confidence level > 0.7 with cluster 1 (ALB, CRP, SELE, TGF-β1, and VCAM-1) and cluster 2 (F8, FGB, PROC, PROS1, SERPINC1). In the first-order non-seed genes, we observed that vascular endothelial growth factor (VEGFA), which belongs to cluster 1, was another switch between both clusters and was interconnected with all seed genes in cluster 1 (at > 0.839) and with four cluster 2 seed DEPs, namely F8 (0.938), FGB (0.907), PROS1 (0.918), and SERPINC1 (0.447).

2.1. 2 Enrichment analysis in the DEPs of death due to ischemic stroke.
Table 1 shows the results of MCODE analysis using GO biological and molecular, KEGG, WikiPaths, PANTHER, and REACTOME protein sets, performed on the first-order genes. We observed a first complex representing an inflammatory response (MCODE1), a second reflecting formation of fibrin clot (MCODE2), and a third representing hemostasis including blood coagulation (MCODE3). Figure 2 shows a bar graph (heatmap) with the top-20 terms that were over-represented in the first order network of death due to IS. Apart from the paths cited above, the following terms were over-represented in descending order of importance: TNF signaling pathway, receptor signaling pathway via Janus kinase-signal transducer and activator of transcription (JAK-STAT), extrinsic apoptotic signaling pathway, and advanced glycation end products and their receptors (AGE-RAGE) signaling pathway in diabetic complications.

2.1.3 Enrichment analysis on cluster 1 genes of death due to ischemic stroke.

Table 2 shows the REACTOME paths that were over-represented in the first-order network of cluster 1 genes. The most important REACTOME paths over-represented (and not shown in figure 2 or Table 2) in cluster 1 were TNF receptor (TNFR)1-induced nuclear factor (NF)-κB signaling pathway, IL-10, IL-4 and IL-13 signaling, TNF-α signaling, IL-6 signaling, IL-1 family signaling, Death Receptor Signaling, and the Toll Like Receptor 3 (TLR3) Cascade.

Figure 3 shows the heatmap (top-10) KEGG pathways that were enriched in cluster 1 indicating that the most important paths over-represented in the network were the TNF-α and IL-17 signaling pathway, lipid and atherosclerosis, TLR, and NF-κB signaling pathway. Figure 4 shows the top-10 InterPro domains which were statistically over-represented in the cluster 1 network, namely the chemokine IL18-like domain, death domain, type I cytokine receptor, CXC chemokine domain and TNFR/nerve growth factor receptor (NGFR) cysteine-rich region.
2.1.4 *Enrichment analysis on cluster 2 genes of death due to ischemic stroke.*

MCODE analysis using KEGG, WikiPaths, PANTHER, REACTOME, and GO molecular and biological terms and performed on the cluster 2 genes showed a first complex representing formation of fibrin clot, a second reflecting the PID- urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR)-mediated (uPA-uPAR) signaling pathway, elastic fiber formation and response to wounding (MCODE2) and a third representing reverse cholesterol transport, plasma lipoprotein particle organization, and protein-lipid complex subunit organization (MCODE3). Table 1 shows the features of both MCODE2 and MCODE3.

Table 2 also shows the top-10 REACTOME paths enriched in the first-order cluster 2 network. Besides the hemostasis and fibrin clot terms listed above, this table shows that post-translational protein phosphorylation, integrin cell surface interactions, intrinsic pathway of fibrin clot formation, platelet degranulation and activation, signaling and aggregation, and a response to elevated platelet cytosolic Ca$^{2+}$ were the most significant paths represented in the cluster 2 network.

Figure 5 shows the top-10 GO molecular terms that were enriched in cluster 2 indicating that (type 1) TGF-β1 receptor binding, endopeptidase inhibitor activity, protease binding, serine-type endopeptidase inhibitor activity, endopeptidase regulator activity, lipoprotein particle receptor binding, and inhibitory SMAD (I-SMAD) binding were the most important molecular functions. Figure 6 displays the top-10 InterPro domains which were statistically over-represented in the first-order cluster 2 network, namely integrin beta N-terminal and subunit, gamma-carboxyglutamic acid-rich (GLA) domain, MAD homology, and SMAD and epidermal growth factor (EGF)-like domains.
2.2 DEP + gene analysis

2.2.1 The DEP/gene PPI network topography of death due to ischemic stroke

Figure 7 shows the first order DEP/gene network of death due to IS. INADL was the only singleton in this network. This network contains 74 nodes and 881 edges which exceeds the expected number of edges (n=227) with a p-enrichment value of 1.0e-16. The average node degree of this network is 23.8 with an average local clustering coefficient of 0.705. The network diameter = 3 and radius = 2, with a characteristic path length = 1.728, network density = 0.344 and heterogeneity = 0.482. The top-6 hubs were in descending order of importance: IL6 (degree=55), ALB (49), TNF (48), SERPINE1 (43), VWF (40) and VCAM1 (39). The same DEPs/genes were the top-5 bottlenecks, and the first 2 non-hub bottlenecks were TGFB1 (0.022) and SELE (0.013). Therefore, the backbone of this network comprises 8 DEPs/DEGs namely IL6, ALB, TNF, SERPINE1, VWF, VCAM1, TGFB1, and SELE.

Using MCL cluster analysis with an inflation parameter of 3.4 we found two communalities as shown in Figure 7: a) a first cluster centered around hemostasis-fibrin clot DEPs/genes including VWF, PROS, PROC, SERPINC1, F8, ALB, SERPINE1, ITGB3, MPG, PROCR, HABP2, COL3A1, FGB, and VKORC1; and b) a second cluster centered around immune DEPs/genes including TNF, IL6, IL10, VCAM1, CRP, SELE, TGFB1, FTH1, and RETN. The major switches in this network were again ALB and VWF, which showed 17 and 21 interconnections at the > 0.9 confidence level with cluster 1 and cluster 2 genes. In the first-order non-seed genes, we again found that VEGFA (belonging to cluster 2) was another switch between both clusters with 19 interactions (at > 0.9) with genes in both clusters.

2.2.2 Enrichment/annotation analysis on cluster 1 DEPs/genes of death due to ischemic stroke.
Table 3 shows the results of MCODE analysis using KEGG, WikiPaths, PANTHER, REACTOME, and GO molecular and biological terms and performed on the cluster 1 DEPs/genes with a first complex showing hemolysis (not shown in Table 3), and a second complex (MCODE2) containing extracellular matrix (ECM) proteoglycans, focal adhesion and ECM organization.

Table 4 shows the top-10 KEGG pathway enriched terms in the first DEP/gene cluster indicating that the most important over-represented paths were complement and coagulation cascades, focal adhesion, proteoglycans, and PI3K-Akt signaling pathway. ESF Figure 1 shows a heatmap (top-16) of the GO_TTRUST transcriptional factors that were enriched in cluster 1 (using Metascape) showing that regulated by SP1 and NFkB1 were the top transcription factor targets. ESF Figure 2 shows the enriched ontology domains in cluster 1.

2.2.3 Enrichment/annotation analysis on cluster 2 DEPs/genes of death due to stroke.

Table 3 also shows the results of MCODE analysis using KEGG, WikiPaths, PANTHER, REACTOME, and GO molecular and biological terms and performed on the cluster 2 DEPs/genes. This analysis showed one molecular complex (MCODE1) which accumulates TNF-α and IL-17 signaling pathways. Table 4 shows the top-10 KEGG pathways enriched in the second DEP/gene cluster. The most over-represented terms were TNF-α, TLR, IL-17, NF-κB, NOD-like receptor, and JAK-STAT signaling pathways. ESF Figure 3 shows a bar graph with the top-16 transcriptional factors (TTRUST) that were enriched in cluster 2 indicating that regulated by RELA (transcription factor p65) and NFKB1 were the top transcription factor targets. ESF Figure 4 shows the enriched ontology domains in cluster 2. ESF Figure 5 shows a heatmap with the top TTRUST factors that were enriched in all DEPs/genes indicating that regulated by RELA and
NFKB1 were the top transcription factor targets. **ESF Figure 6** shows the enriched ontology domains in all DEPs/genes combined.

inBio Discover was employed to delineate which DOID diseases are over-represented in the DEPs/gene network. **Table 5** displays the top-10 DOID annotations showing that the DEPs/genes are enriched in cardiovascular disease, blood coagulation disease, thrombosis and immune and autoimmune disorders. **ESF Figure 7** shows the extended network constructed with inBio Discover and some top DOID annotations. **ESF Figure 8** showed the enriched GO terms of cellular components, including plasma membrane, blood microparticles, platelet alpha granules and the endoplasmic reticulum lumen.

### 2.2.4 Building a composite network with multiOomics enrichment analysis

**ESF Figure 9** shows a MultiOomics network (using InAct, mirNET, TTRUST and KEGG metabolic reactions) built using DEPs, genes, and miRNA (metabolic markers are not significant) in OmicsNet. The network comprises 1000 nodes and 2180 edges. **Table 6** shows the results of OmicsNet enrichment analysis performed on the networks shown in ESF Figure 9. The REACTOME pathways and PANTHER biological process enrichment analyses showed that the most important paths revolved around the metabolism of RNA, mRNA, RNA splicing, and nonsense mediated decay and nonsense Mediated Decay Enhanced by the Exon Junction Complex. A search for regulatory relationships using TTRUST shows that the top-3 over-represented transcriptional networks in the network were SP1 (82 hits), NFKB1 (45), and RELA (43). For example, NFKB1 regulates seed DEPs in the immune (CRP, IL6, TNF, TGFB1, SELE, VCAM1) and hemostasis (VWF, F8 and SERPINE1) subnetworks. **ESF Figure 9** shows the targeted integration of these three regulating actors in the PPI network (shown in green colors).
Finally, we built another MultiOmics network (ESF Figure 10) using all DEPs and genes and employed the Regulation Explorer to detect miRNA-gene interactions. This analysis shows that hsa-mir-16-5p (174 hits) and hsa-mir-26b-5p (170) were by far the most important interacting miRNAs. ESF Figure 10 shows the targeted integration of these two miRNAs in the network.

3. Discussion

The networks and subnetworks of death due to stroke

The first major finding of this study is that the PPIs network of DEPs and DEPs/genes of death due to IS show a high connectivity and two interconnected subnetworks, namely a first centered around immune genes and a second around hemostasis-coagulation genes. All query DEPs/genes participated in these networks except INADL. The backbone of this network consists of DEPs/genes which contribute to both subnetworks, namely IL6, TNF, TGFβ1, VCAM, and SELE as authorities in the immune subnetwork, and ALB, SERPINE1, and VWF in the hemostasis subnetwork. Moreover, ALB and VWF are important switches that connect both subnetworks because these DEPs show many significant interactions with proteins in both communities. Therefore, it appears that death to IS may be predicted by an integrated response in a network which comprises strongly interconnected immune and hemostasis subnetworks. This indicates that both the immune response (as indicated by increased IL-6, IL-10, TNF-α, VCAM-1, SELE, and CRP but lowered TGF-β1 and ALB) and the activated hemostasis, thrombosis and coagulation pathways (as indicated by increased F8, VWF, and FBG but lowered PROC, PROS1, SERPINC1 and ALB levels) [8] are intertwined phenomena leading to death due to IS. The strong interconnections among the immune and hemostasis subnetworks have probably an evolutionary
origin [47]. We will now discuss both the significant biological functions, paths, molecular complexes, and transcriptional factors enriched in the networks.

*Terms over-represented in the immune subnetwork.*

The second major finding of this study is that the most significant paths and functions enriched in the networks of death due to IS were the inflammatory and NF-κB signaling pathways, NFKB1/RELA transcriptional factors, TNF-α and IL-17 signaling, and the TLR, TGF-β1, nucleotide-binding and oligomerization domain (NOD) and JAK-STAT pathways. These results indicate that altered expression of these pathways, and transcriptional factors may lead to death due to IS.

There is now evidence that in IS, NF-κB may be a key factor for the transcriptional induction of cellular adhesion molecules, including SELE and VCAM-1, pro-inflammatory cytokines, including IL-6 and TNF-α, CRP, and FTH1, growth factors including TGF-β1, and coagulation factors including F8, PAI1, uPA, tissue factor and fibronectin [47,48]. Transient focal cerebral ischemia is accompanied by NF-κB activation in the nuclei of striatal and cortical neurons in the ischemic hemisphere [49]. It is important to note that ischemia-induced astroglial NF-κB may have neurodegenerative effects, whereas constitutive neuronal nuclear factor kappa B subunit 1 (NFKB1) may have neuroprotective effects [50].

In animal models of middle cerebral artery occlusion, activation of astroglial NF-κB is downstream of TLR2 activation and a deficiency in TLR2/4 reduces the neurodeficits and IS size [50]. Moreover, models of focal cerebral ischemia show that increased NF-κB is associated with IS severity and size and that there may be a causative association between both factors, whereby induced reductions in NF-κB levels are accompanied with lowered IS size and neurodeficits.
Inhibition of NF-κB (through administration of caffeic acid phenethyl ester, mycophenolate, atorvastatin, and cephalexin may attenuate oxidative stress and neurodegeneration due to middle cerebral artery occlusion [52]. Moreover, the promoter variant (rs11940017, -1727 C>T) of the NFKB1 gene may affect IS susceptibility in Korean population [53].

Furthermore, there is evidence that, in IS, the deleterious effects of increased NF-κB are associated with RELA activation [48], which is the second transcription factor which is highly significantly enriched in our PPI network. RELA plays a key role in the activation of NF-κB, the translocation of the latter to the nucleoplasm, while the RELA-NFKB1 complex mediates gene expression of many cytokines (UniPro UniProtKB - Q04206 (TF65_HUMAN) (uniprot.org). Moreover, the apoptotic responses caused by NF-κB are dictated by acetylation of RELA in Lys310 [54] and RELA, but not p50, knockouts show a decreased infarct size [55].

The TLR2/4 complexes play a key role in IS with increased expression of both receptors being associated with the inflammatory response and progression of infarct volume and ischemic damage [56]. Both TLR levels (as assessed in peripheral blood monocytes using flow cytometry) are associated with increased plasma levels of IL-6, TNF-α, VCAM-1, and the clinical outcome and lesion volume [57]. It is interesting to note that in IS patients, serum levels of fibronectin, heat shock protein (HSP)60 and HSP70 are endogenous ligands leading to TLR2/4 activation [57]. Likewise, the inflammatory response during stroke is attenuated by blockade of the TLR2/4 complexes and cellular fibronectin. In TLR4 knockout mice smaller stroke sizes and better neurocognitive functions are observed [58,59]. All TLR pathways activate NF-κB [56,60] indicating that activation of the TLR2/4 pathways and NF-κB signaling are interrelated phenomena. This suggests that the cumulative effects of both TLR2/4 and NF-κB signaling pathways may confer risk towards death due to IS. There are also reports that TLR4 genetic
variants (e.g. TLR4-119A allele) are associated with an increased risk of IS [61]. Moreover, it is important to note that vitamin D3, which in our studies was associated with death due to IS, attenuates TLR2/4 expression and signaling, thereby preventing the translocation of p65 to the nucleus and, consequently, attenuating inflammatory responses [56].

Soon after IS onset, microglia cells and circulating monocytes are activated and, consequently, increased release of TNF-α and IL-6 may be detected in the brain, cerebrospinal fluid and bloodstream [8]. Increased TNF-α levels in CSF and blood are significantly associated with stroke outcome including the Barthel Index and Scandinavian Stroke Scale (SSS) [62]. The plasma levels of TNF-α, which are observed in IS patients, may impact neuronal function and viability even leading to neuronal death [63]. A recent meta-analysis shows that TNF-α is increased in Asian and Caucasian IS patients (overall SMD =0.65, 95% CI =0.29, 1.01) and that the TNF-α-308 G > A (rs1800629) genetic variant is associated with increased risk of IS [64]. IS is accompanied by an increased expression of IL-17 and IL-17RC in the serum in association with increased IL-6 and granulocyte-monocyte colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) [65]. It is thought that the IL-17 – IL-17R pathway plays a key role in secondary post-stroke damage via a) effects on neutrophil infiltration in cerebral parenchyma thereby promoting damage and thrombosis; b) effects on tight junctions with blood-brain-barrier (BBB) breakdown and induction of neuronal apoptosis, and c) synergistic effects with IL-6 [66]. Moreover, a polymorphism of the IL17RC gene is associated with a poorer prognosis of IS [65].

There are now some reports that in experimental models of IS, the JAK2-STAT3 pathway is activated and contributes to neuronal damage [67-70]. Middle cerebral artery occlusion is accompanied by increased concentrations of TNF-α, high mobility group box B1 (HMGB1),
phosphorylated-JAK2/JAK2 and STAT3/STAT3 in the brain. Blocking JAK2, STAT3 and the JAK2/STAT3 signaling pathway significantly reduces IS-associated inflammatory responses [71]. Also, Wang and coworkers [72] reported that, in an IS model, attenuation of the JAK-STAT pathway reduces apoptosis in neuronal cells and loss of neurological functions. Cytokines including IL-6 and IL-10 activate Janus kinases causing translocation of STAT to the nucleus which, in turn, lead to changes in expression of a great number of immune and wound healing genes [73].

NOD-like receptors are a family of cytoplasmic receptors which sense bacterial motifs and danger signals (including uric acid and ATP) and trigger an innate immune response by activating NF-κB and mitogen-activated protein kinase (MAPK) [74,75]. In the middle cerebral artery occlusion model, the expression of NOD2 is significantly elevated and ablation of the NOD2 gene reduces stroke size and inflammation as indicated by lowered expression of NF-κB, MAPK, IL-6, and TNF-α [75].

Our REACTOME path classifications revealed that our DEP network was highly significantly associated with IL-10, IL-4 and IL-13 pathways. We discussed before that increased activity of the IL-10 pathway in non-survivors may be part of a compensatory immune-regulatory mechanism which counterbalances an overzealous inflammatory response [8]. Elevated levels of IL-10 are often associated with a better functional outcome. For example, subjects with reduced plasma IL-10 in the first hours after IS are at increased risk to develop neurological symptoms two days later [76]. Some IL10 genetic variants are associated with increased risk of IS, including the IL-10 rs1800896 variant [77]. IL-4 also has anti-inflammatory effects and drives macrophages from a M1 proinflammatory phenotype to a M2 phenotype with homeostatic, repair and immune regulatory properties explaining that IL-4 administration may improve recovery in a mouse stroke
model [78]. *IL4* KO mice show a worsened neurological outcome and increased brain damage following cerebral ischemia [79]. In IS, intracerebral delivery of IL-13, an anti-inflammatory cytokine, drives macrophages and microglia into the alternative activation state [80]. Nevertheless, high levels of anti-inflammatory cytokines such as IL-10 may sometimes be accompanied by a less favorable outcome, including increased risk of infections [81].

One of the major bottlenecks in the PPI network is TGF-β. This cytokine is elevated in the brain following IS and may exert anti-inflammatory, anti-apoptotic and neuroprotective effects thereby improving repair mechanisms and favoring nerve regeneration [82-84]. There are now some publications showing that genetic *TGFBI* variants are associated with IS [85]. Moreover, the effects of TGF-β1 on multiple target genes (including ECM) are mediated via the SMAD signaling pathway [86,87], which was significantly enriched in the hemostasis subnetwork list, albeit SMAD/MAD did not make the top-5. Importantly, the TGF-β/SMAD2/3 signaling pathway has neuroprotective properties for example by elevating Bcl-2 and lowering caspase-3 expression and decreasing microglial activation via NF-κB inhibition [88,89].

In a rat model of cerebral ischemia/reperfusion, SMAD3 administration may downregulate inflammatory and pro-apoptotic genes, suggesting that the TGF-β/SMAD pathway is a possible drug target [88]. All in all, the lowered levels of TGF-β1 in IS non-survivors versus survivors [8] may contribute to the pathways leading to death due to IS.

VCAM-1, another hotspot of the backbone of the PPI network, plays a critical role in the inflammatory response following IS [90] for example through adhesion of leukocytes to endothelial cells and transendothelial migration via interactions with integrin subunits [91]. Due to a fenestrated endothelium, the choroid plexus is the entry site for patrolling lymphocytes — mostly CD4+ central memory T cells — in the healthy brain [92]. To promote leukocyte
trafficking, the choroid plexus epithelium constitutively expresses intercellular adhesion molecule (ICAM)-1 and VCAM-1, which, together with the mucosal vascular addressin cell adhesion molecule, are upregulated in stroke [49]. In IS, intracranial VCAM-1 levels are associated with infarct and edema size [93]. Cell adhesion molecules (CAM) KO models show a reduced infarct size and administration of anti-CAM antibodies may decrease infarct size [94]. Increased levels of VCAM-1 and IL-6 predict a new vascular incident [95] and, thus, may increase risk of death due to IS.

3.1 Terms and functions over-represented in the hemostasis subnetwork

The second most important subnetwork in death due to IS was centered around hemostasis, thrombosis and coagulation genes, which were enriched especially in fibrin clot or the clotting cascade, TGF-β binding, uPA and uPAR-mediated (PID-uPA-uPAR) signaling pathway, ECM proteoglycans, integrin cell surface interactions, and platelet activation, aggregation and degranulation. Although abnormalities in the hemostasis axis are not a common cause of IS [96-98], perturbations are seen following stroke onset and these may aid as biomarkers in diagnosis and severity of IS and prediction of the treatment response. This is further substantiated by our findings that a response to wounding is over-represented in the hemostasis subnetwork. It could be argued that a combined deficiency in the PROC, PROS1 and SERPINC1 proteins in the hemostasis network may contribute to the response to wounding. Nevertheless, deficits in these proteins are not a common cause of IS [99], although our studies suggest that they may contribute to death due to IS.

One major hotspot of the backbone of the PPII network and a major connector of both subnetworks is VWF, which shows many interactions with genes from both the immune and
hemostasis networks. Such data agree with the view that VWF mediates the crosstalk between immune cells and hemostasis mechanisms and contributes to inflammation including vascular inflammation [100,101]. The VWB factor is released during the rupture of the endothelial layer of the vessels whereby the consequent exposure of collagen to platelets leads to clot formation [102]. Consequently, endothelial cells release VWF, P-selectin, SELE, and inflammatory mediators [103]. VWF promotes platelet adhesion to the damaged site by forming a molecular bridge between the subendothelial collagen matrix and the platelet surface receptor complex GPIb-IX-V [101]. VWF levels are increased in IS patients and are associated with the cardioembolic and large-vessel disease subtypes [104]. Additionally, VWF levels are associated with severity of arterial thrombus formation and poor functional outcomes [105, 106]. Furthermore, VWF may function as a biomarker of the response to thrombolytic or endovascular treatment in IS patients [106, 107]. Variations in the VWF gene (Sma I) may be associated with an increased risk of IS [108]. Preclinical and clinical studies using VWF antagonists and combining the latter with tPA could prevent microvascular thrombus formation thereby attenuating the progression of IS [106]. Also, other authors proposed that targeting VWF-mediated platelet activation and adhesion is a new drug target to treat IS [109].

Fibrinogen (FBG) is one of the hemostasis biomarkers with an essential role in the thrombosis process because it is related to platelet aggregation after injury and inflammation [110,111]. FBG is released from the liver to the bloodstream and is cleaved by thrombin at the damaged site, resulting in fibrin formation. Fibrin is one of the main constituents of blood clots and provides remarkable biochemical and mechanical stability [111]. FBG and CRP levels can independently predict the risk of early death in middle-aged IS patients emphasizing the role of inflammation and coagulation in the evolution of IS. For each 10 mg/dL increase in FBG levels
there was a 18% higher risk of dying, while for 1 mg/L increase in CRP the additive risk was 18%. FBG levels >490 mg/dL and CRP levels >18 mg/L were the optimal points that discriminated those who died from survivors [112]. Another study showed that hyperfibrinogenemia, defined as plasma FBG concentration >350 mg/dL, predicts the long-term risk of death in IS patients [113]. Moreover, FBG has been used to evaluate the long-term outcome and the size of the clot burden in patients after IS [114,115]. Furthermore, an increase in FBG levels is observed after IS and is associated with infarct size and outcome [116-118]. Elevated hemostatic markers after acute IS stroke identify patients with increased risk for mortality independently of IS severity or stroke type [119]. Higher concentrations of fibrinopeptide A, b-thromboglobulin, prothrombin fragments 1 and 2, thrombin–anti-thrombin complexes, platelet factor 4 and VWB factor have all been associated with a worse clinical course in IS and increased mortality [119-121]. In addition, patients with high PAI-1 levels are less likely to achieve recanalization after receiving tPA and experience poorer outcomes [122].

Another possible major pathway which was found using enrichment analysis is the uPA-uPAR pathway. This pathway is activated in the periphery of growth cones of the injured neurons in IS brain where it induces repair mechanism [123]. The binding of uPA to its receptor promotes β1-integrin recruitment to the plasma membrane with consequent activation of “small Rho GTPase Rac1 and Rac1-induced axonal regeneration” [123]. Since this process is regulated by the low-density lipoprotein receptor (LRP1), it was proposed that the uPA-uPAR-LRP1 axis is another possible drug target in IS [123] and by inference may be a new drug target to prevent death due to IS. Moreover, recombinant uPA may protect the integrity of pre- and postsynaptic terminals and astrocytic elongations against the detrimental effects of IS [124]. Unfortunately, uPA also increases the production of reactive oxygen species and NADH oxidases (Nox1 and Nox4) and
enhances superoxide production by neutrophils, findings which suggest that reducing uPA functions may be beneficial [125].

Our enrichment and annotation analyses revealed that the hemostasis subnetwork genes were significantly associated with ECM proteoglycans and integrin cell surface interactions, which are components of the BBB. These functions are impacted by IS, the consequent vasogenic edema, early angiogenesis, inflammation, and reperfusion injury [126-129]. These IS-induced processes strongly impact the BBB, resulting in breakdown of the tight junctions and paracellular barrier and increased BBB permeability which may further worsen vasogenic edema and neuroinflammation through increased entry of inflammatory mediators and activated T cells into the brain [130, 131]. As observed in our paper and previously [131] such processes may lead to increased mortality due to IS. Moreover, proteoglycans, integrins and fibronectin are key ECM adhesion receptors which integrate external and internal signals, and regulate global cellular processes, cellular signaling, and cell growth, proliferation, migration, and survival [126]. The ECM regulates the tight junctions, neurons, astrocytes and the vasculature and plays a key role in wound healing, cell homeostasis, and tissue and neuronal regeneration [132]. Importantly, the proteoglycan-integrin-ECM complex and related BBB functions including tight junctions are now considered to be new drug targets in the treatment of IS for example by targeting integrins and MMPs [128,129].

3.2 Interactions, pathways and functions which bridge the immune and hemostasis subdomains.

Out network analyses showed that not only the VWF (as discussed in the previous section) but also ALB is a major controller gene between both subnetworks of death due to IS and, consequently, that also ALB may be an important drug target. ALB has anti-inflammatory, antioxidant and neuroprotective capacities and thus plays a role in the immune subnetwork,
although a second clustering analysis performed in our study allocated ALB in the hemostasis network. ALB shows also antiplatelet aggregability and is a carrier for two anti-clotting compounds, namely heparin cofactor and SERPINC1 [133, 134]. Subjects with low ALB display increased primary hemostasis, enhanced platelet aggregation and clot formation, explaining that low ALB levels observed in non-survivor IS patients may increase the vulnerability to develop venous thromboembolism [133]. Importantly, baseline ALB levels reflect a chronic inflammatory state, which is already present weeks before the IS (because the half-life of ALB is 21 days). All in all, lowered ALB levels may predispose towards interrelated aberrations in both the immune and hemostasis subnetworks, thereby, increasing risk of death due to IS.

In the enlarged giant network, VEGFA is another switch between the immune and hemostasis communalities. This gene is a member of the VEGF family and the protein acts as a mitogen, thereby activating endothelial cells and regulating neuronal cells [135]. VEGFA is implicated in the pathophysiology of atherosclerosis and, in stroke, VEGFA is elevated in the ischemic penumbra, and mediates vessel and neuron repair and remote plasticity in ischemic brain regions [135]. Treatment with VEGFA coupled with stem cells may show therapeutic effects in animal stroke models. Moreover, there is an association between IS and different genetic variants of VEGF genes (e.g. -2578C>A and 936C>T variants) [136].

There are many more pathways and functions which link inflammation and coagulation, including TLRs (impact coagulation, platelet activity and aggregation, and thrombosis) [137], NOD2 signaling (enhances platelet activation and thrombosis) [138], TNF-α signaling (activates coagulation, fibrinolysis, neutrophil degranulation, and release of secretory phospholipase A2 predominantly mediated by the p55 TNFR) [139], platelets (platelet degranulation causes increased cIMT and, thus, increased inflammatory atherosclerotic processes) [47, 140], protease
activated receptors and thrombin, complement, neutrophil extracellular traps, and microparticles [141].

Moreover, our TTRUST enrichment analysis shows that not only NF-κB and RELA (discussed in the previous sections), but also SP1 is a major regulator of both the immune and hemostasis subnetworks. NF-κB is not only critically involved in modulating inflammatory processes but also in thrombotic responses [47]. Thus, NF-κB activation increases the thrombogenic potential, activates platelets, and promotes coagulation, microthrombi formation, immunothrombosis and thrombo-inflammatory disease [47]. In addition, F8, PAI1, uPA and F3 are target genes of NF-κB. SP1 or transcription factor Sp1 (or specificity protein 1) regulates the expression of house-keeping genes which are involved in immune responses, apoptosis, chromatine remodelling, cell differentiation and growth [142]. This transcription factor regulates different subnetworks including the immune response (including TNF-α), MAPK and JAK-STAT pathways, platelet activation, ECM, and blood vessels [142].

Our REACTOME pathway and PANTHER process enrichment analyses performed on all markers including miRNA levels revealed the strong impact of translation, RNA, metabolism of mRNA, RNA splicing, and nonsense mediated decay on the interactome of death due to IS, indicating that dysfunctions in post-ischemic translation regulation are involved. During ischemia and brain cell injury, translation may arrest due to lack of ATP and changes in translational regulation at the mRNA level and the ribosomal network may develop which may cause a multitude of aberrations in the downstream PPI and metabolic network modules [143,144]. The nonsense-mediated decay pathway degrades transcripts with premature stop codon thereby reducing errors in gene expression. Failures in this surveillance system may be accompanied by increased synthesis of abnormal, including toxic, proteins [145].
It is interesting to note that both miRNAs, which are altered in death due to IS, regulate immune functions with hsa-mir-10a regulating IL-8, IL-6, TNF-α, GATA6, apoptotic pathways, and hsa-mir-34b regulating innate immunity (target mining in www.mirbase.org). Our study also showed that the expression of the most important miRNA, which is over-represented in death due to IS (hsa-mir-16-5p), was found to be increased in IS [146] and to regulate NF-κB transcription [147]. Moreover, also the second most important miRNA (hsa-mir-26b-5p) is part of a long noncoding RNA (LncRNA)-miRNA-mRNA network of IS [148] and inhibits NF-κB expression [149]. Some miRNAs are associated with IS risk factors including hypertension (miR-155), atherosclerosis (miR-21, miR-126, miR-143), atrial fibrillation (miR-26), diabetes mellitus (miR-124a, miR-126), and dyslipidemia (miR-33, miR-122), while some miRNA antagonists have the potential to act as neuroprotective molecules [150]. Elevated expression of miR-15a, miR-16, and miR-17-5p in the serum is strongly associated with IS [151].

4. Methods

4.1 Selection of seed proteins, genes, miRNA and metabolic markers

“This study is a secondary data analysis on existing data using open, deidentified and non-coded data sets and, therefore, this is non-human subjects research which is not subject to the Institutional Review Board (IRB) approval.” In our previous case-control studies, we have identified DEPs and metabolic pathways in IS patients who died three months to one year after the IS as compared with IS survivors [8]. We found that the markers of death due to IS after one year were the same as those after three months and vice versa [8] and, therefore, these biomarkers reflect pathways leading to death within one year after IS. The clinical features and socio-demographic data of the patients are shown elsewhere [8, 13, 152]. We were able to include 15
proteins which were significantly altered in non-survivors versus survivors following stroke, namely SERPINC1, PROC, PROS1, VWF, coagulation F8, FBG, CRP, ALB, TNF-α, IL-10, IL-6, TGF-β1, FTH1, VCAM-1, and SELE [8, 13, 152]. The downregulated DEPs were SERPINC1, PROC, PROS1, ALB, and TGF-β1, whereas the other DEPs were upregulated. In our studies, we also delineated three Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways of death due to IS, namely C00103 (glucose), C05443 (vitamin D) and Hsa04979 (cholesterol) [8, 13, 152]. Moreover, we added a) a number of genes which are associated with death due to IS as reviewed in the Introduction, namely SERPINE1, ITGB3, MPG, PROCR, HABP2, COL3A1, FGB, VKORC1, INADL, and RETN; and b) two miRNA which are associated with death due to IS, namely MIR10A (miR-10a rs3809783) and MIR34B (miR-34b/c rs4938723).

4.2 PPI network construction, and enrichment and annotation analyses.

We constructed three network types, namely a first based on the DEPs delineated in our clinical studies, a second on the combined DEPs + genes; and a third on all data combined. PPI networks were constructed with network expansion as explained previously [153]. In brief, IntAct Molecular Interaction Database (https://www.ebi.ac.uk/intact/), a primary database based on peer-reviewed publications, and STRING version 11.0 (https://string-db.org), a predictive database, were used to construct the networks. We constructed zero-order PPIs (seed proteins only) and first-order PPIs (50 interactions in the first shell, none in the second shell) (set organism: homo sapiens, and a minimum required interaction score of 0.400). The network characteristics (number of nodes and edges, etc) were computed using STRING and the Cytoscape plugin Network Analyzer. The backbone of the network was delineated as consisting of the top hubs (nodes with the highest degree) and the top non-hub bottlenecks (nodes with the highest betweenness centrality). The
physical interactions between the proteins/genes/mir were visualized using STRING, Cytoscape (https://cytoscape.org), Gene Ontology (GO) net (https://tools.dice-database.org/Gonet/), OmicsNet (OmicsNet), inBio Discover (https://inbio-discover.com/), and Metascape (https://metascape.org). Markov Clustering (MCL) was conducted using STRING to detect communalities of highly interconnected nodes with similar attributes and functions. Separate enrichment/annotation analyses were conducted on the formed communalities and upregulated and downregulate genes as well.

The different PPI networks were examined for their enrichment scores and annotated terms employing a) STRING to establish the GO biological processes and molecular functions, and KEGG (https://genome.jp/kegg/) and REACTOME (the European Bio-Informatics Institute Pathway Database; https://reactome.org) pathways; b) Enrichr, a gene list enrichment analysis tool (https://maayanlab.cloud/Enrichr/) to establish and visualize (via Appyter) GO molecular functions, KEGG pathways, and InterPro domains (InterPro (ebi.ac.uk)); c) OmicsNet (using InAct, mirNET, TTRUST and KEGG metabolic reactions) to establish REACTOME and PANTHER (PANTHER - Gene List Analysis (pantherdb.org) biological processes, and the OmicsNet regulation explorer to establish TTRUST transcriptional regulatory relationships (www.grnpedia.org/trrust); d) Metascape to establish and visualize the over-represented REACTOME, KEGG, PANTHER, and Wiki (WikiPathways - WikiPathways) pathways; e) inBio Discover to establish DOID human disease phenotypes (Disease Ontology - Institute for Genome Sciences @ University of Maryland (disease-ontology.org); and f) R package ClusterProfiler to establish the cellular components over-represented in the network. In addition, Metascape was combined with Molecular Complex Detection (MCODE) to delineate smaller molecular complexes and to visualize enriched ontology clusters. The latter are based on accumulative
hypergeometric p-values which are used for filtering whereby the remaining terms are hierarchically clustered into a tree, which based on a 0.3 kappa score threshold, is casted into term clusters. OmicsNet was used to build a composite network (consisting of DEPs, genes, miRNA and metabolic paths) coupled with multiOmics enrichment analysis. We use false discovery rate (FDR) corrected p-values.

5. Conclusions

This study defined a) the pathways and molecular processes and ensuing pathoclinical conditions (blood coagulation and thrombosis, and immune system and cardiovascular system disease) leading to death due to IS; and b) the possible drug targets which should be treated to prevent death due to IS. Foremost, the major switches between the immune and hemostasis subnetworks (ALB and VWF) could be targeted to damp the coordinated response in both subnetworks. Nevertheless, treatment with intravenous ALB did not improve IS outcome and may even cause pulmonary edema and intracerebral hemorrhage [154]. Targeting VWF, on the other hand, may be a more promising approach by reducing stroke recurrence, thrombotic risk, platelet aggregation and VWF-associated inflammation [155-157]. Improving remote plasticity in the ischemic hemisphere by targeting VEGFA, promoting neuronal repair by targeting the TGF-β1/SMAD, and targeting the proteoglycan-integrin-ECM complex and related BBB functions are other possibilities which may reduce IS-induced neuronal damage and promote the repair of affected cells.

Furthermore, the most influential genes of the network are other possible drug targets and comprise (besides ALB, VWF and TGFB1) IL6, TNF, VCAM1, IL10, and SELE. However, selectively targeting any of these backbone genes may improve only part of the network, although
combinatorial treatment with other pathways may be beneficial. Targeting the anti-inflammatory cytokines IL-10, IL-13, and IL-4, which were shown to reduce infarct size, is another option. In this respect, IL-10 would be a good candidate because this cytokine is part of the backbone of the PPI network, although in some conditions this cytokine may increase risk of infections.

Targeting the pathways and molecular complexes that are involved in death due to IS may provide better target options because these pathways/processes govern many players in the PPI network. Candidates are the TLR2/4, TNF-α, JAK-STAT and NOD pathways. However, since all these pathways appear to play a role in death due to IS, a combinatorial treatment targeting some of some of these pathways appear to be indicated. Alternatively, targeting the transcription factors (NFκB/RELA or SP1) which govern a large part of the proteome network may be an adequate strategy. Recently, Howell and Bidwell [158] reviewed the potential benefits of targeting NF-κB in ischemia-reperfusion injury in the brain. Finally, this study also observed that hsa-mir-16-5p and hsa-mir-26b-5p may be targeted or used as treatments. For example, hsa-mir-26b-5p is part of a LncRNA-miRNA-mRNA network of IS and appears to regulate the transcriptome and proteome of death due to IS. Nevertheless, treatment of IS and death due to IS should also target the metabolic risk factors glucose, HDL-cholesterol, and 25(OH)D.

Based on our results, we would propose that current treatments may be improved by targeting VWF, VEGFA, proteoglycan-integrin-ECM complex, TGF-β1/SMAD, NFκB/RELA and SP1. The most adequate future approach will consist of using novel compounds, which modulate the coregulation of the proteome of death due to IS by targeting the miRNAs and the transcriptional factors established in our study.
Author’s contributions: All the contributing authors have participated in the manuscript. M.M. designed the study and M.M., K.P. and A.S. performed the network, enrichment and annotation analyses. All authors (M.M., K.P., A.S., and E.M.V.R.) contributed to interpretation of the data and writing of the manuscript, have read and agreed to the published version of the manuscript.

Funding Statement: This work was supported by the Russian Science Foundation (Grant # 20-65-46021).

Compliance with ethical standards: The study was conducted according to international ethics and privacy laws.

Institutional Review Board Statement: This study is a secondary data analysis on existing data using open, deidentified and non-coded data sets and, therefore, this is non-human subjects research, which is not subject to IRB approval.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the article.

Conflict of interest: The authors have no conflict of interest with any commercial or other association in connection with the submitted article.

References

[1] Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart
Association. *Circulation*. **2018**, 137, 67–492.

[2] Kuriakose, D.; Xiao, Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. *Int J Mol Sci.* **2020**, 21, 7609. doi: 10.3390/ijms21207609.

[3] Sacco, R.L. Risk factors, outcomes, and stroke subtypes for ischemic stroke. *Neurology*. **1997**, 49, S39-44.

[4] Chen, X.; Zhou, L.; Zhang, Y.; Yi, D.; Liu, L.; Rao, W.; Wu, Y.; Ma, D.; Liu, X.; Zhou, X.H.; Lin, H.; Cheng, D.; Yi, D. Risk factors of stroke in Western and Asian countries: a systematic review and meta-analysis of prospective cohort studies. *BMC Public Health*. **2014**, 14, 776.

[5] Kleindorfer, D.O.; Towfighi, A.; Chaturvedi, S.; Cockroft, K.M.; Gutierrez, J.; Lombardi-Hill, D.; Kamel, H.; Kernan, W.N.; Kittner, S.J.; Leira, E.C.; Lennon, O.; Meschia, J.F.; Nguyen, T.N.; Pollak, P.M.; Santangeli, P.; Sharrief, A.Z.; Smith, S.C. Jr.; Turan, T.N.; Williams, LS. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. *Stroke*. **2021**, 52, e364-e467. doi: 10.1161/STR.0000000000000375. Erratum in: *Stroke*. **2021**, 52, e483-e484.

[6] Zhou, X.; Yu, F.; Feng, X; Wang, J.; Li, Z.; Zhan, Q.; Xia, J. Immunity and inflammation predictors for short-term outcome of stroke in young adults. *Int J Neurosci*. **2018**, 128, 634–639. doi:10.1080/00207454.2017.1408614.
[7] Wiseman, S.; Marlborough, F.; Doubal, F.; Webb, D.J.; Wardlaw, J. Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: Systematic review and meta-analysis. *Cerebrovasc Dis* **2014**, *37*, 64–75. doi: 10.1159/000356789.

[8] Lehmann, A.L.C.F.; Alfieri, D.F.; de Araújo, M.C.M.; Trevisani, E.R.; Nagao, M.R.; Pesente, F.S.; Gelinski, J.R.; de Freitas, L.B.; Flauzino, T.; Lehmann, M.F.; Lozovoy, M.A.B.; Breganó, J.W.; Simão, A.N.C.; Maes, M.; Reiche, E.M.V. Immune-inflammatory, coagulation, adhesion, and imaging biomarkers combined in machine learning models improve the prediction of death 1 year after ischemic stroke. *Clin Exp Med.* **2021a**; doi: 10.1007/s10238-021-00732-w.

[9] Tzoulaki, I.; Murray, G.D.; Lee, A.J.; Rumley, A.; Lowe, G.D.; Fowkes, F.G. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. *Circulation* **2007**, *115*, 2119–2127. doi: 10.1161/CIRCULATIONAHA.106.635029.

[10] Alakbarzade, V.; Taylor, A.; Scully, M.; Simister, R.; Chandratheva, A. Utility of current thrombophilia screening in young patients with stroke and TIA. *Stroke and Vasc Neurol.* **2018**, *3*, 231-236. doi:10.1136/svn-2018-000169.

[11] Hashem, S.S.; Helmy, S.M.; El-Fayomy, N.M.; et al. Predictors of stroke outcome: the role of hemorheology, natural anticoagulants, and serum albumin. *Egypt J Neurol Psychiatr Neurosurg.* **2018**, *54*, 18. doi:10.1186/s41983-018-0019-x.
[12] Donkel, S.J.; Benaddi, B.; Dippel, D.W.J.; Ten Cate, H.; de Maat, M.P.M. Prognostic Hemostasis Biomarkers in Acute Ischemic Stroke. *Arterioscler Thromb Vasc Biol*. **2019**, *39*, 360-372. doi: 10.1161/ATVBAHA.118.312102.

[13] Lehmann, A.L.C.F.; Alfieri, D.F.; de Araújo, M.C.M.; Trevisani, E.R.; Nagao, M.R.; Pesente, F.S.; Gelinski, J.R.; de Freitas, L.B.; Flauzino, T.; Lehmann, M.F.; Lozovoy, M.A.B.; Breganó, J.W.; Simão, A.N.C.; Maes, M.; Reiche, E.M.V. Carotid intima media thickness measurements coupled with stroke severity strongly predict short-term outcome in patients with acute ischemic stroke: a machine learning study. *Metab Brain Dis*. **2021b**, doi: 10.1007/s11011-021-00784-7.

[14] Brott, T.; Adams Jr, H.P.; Olinger, C.P.; et al. Measurement of acute cerebral infarction: a clinical examinations scale. *Stroke*. **1989**, *20*, 864-870. doi: 10.1161/01.str.20.7.864.

[15] Bonita, R.; Beaglehole, R. Recovery of motor function after stroke. *Stroke*. **1998**, *19*, 1497–1500. doi: 10.1161/01.str.19.12.1497.

[16] Adams Jr, H.P.; Davis, P.H.; Leira, E.C.; et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). *Neurology*. **1999**, *53*, 126–131. doi: 10.1212/wnl.53.1.126.

[17] Johnston, K.C.; Wagner, D.P.; Haley, E. C. Jr.; Connors, A.F. Jr.; RANNTAS Investigators. Randomized Trial of Tirilazad Mesylate in Acute Stroke. Combined clinical and imaging
information as an early stroke outcome measure. *Stroke.* **2002**, 33, 466-472. doi:10.1161/hs0202.102881.

[18] Weimar, C.; König, I.R.; Kraywinkel, K.; Ziegler, A.; Diener, H.C.; German Stroke Study Collaboration. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. *Stroke* **2004**, 35, 158-162. doi:10.1161/01.STR.0000106761.94985.8B.

[19] Bustamante, A.; Simats, A.; Vilar-Bergua, A.; García-Berrocoso, T.; Montaner J. Blood/Brain Biomarkers of inflammation after stroke and their association with outcome: from C-reactive protein to damage-associated molecular patterns. *Neurotherapeutics.* **2016**, 13, 671-684. doi:10.1007/s13311-016-0470-2.

[20] GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **2019**, 18, 439-458. doi: 10.1016/S1474-4422(19)30034-1.

[21] Donkor, E.S. Stroke in the 21st Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. *Stroke Res Treat.* **2018**, 27, 2018:3238165. doi: 10.1155/2018/3238165.

[22] Heller, R.F.; Langhorne, P.; James, E. Improving stroke outcome: the benefits of increasing availability of technology. *Bull World Health Organ.* **2000**, 78, 1337-43.
[23] Brønnum-Hansen, H.; Davidsen, M.; Thorvaldsen, P.; Danish MONICA Study Group. Long-term survival and causes of death after stroke. *Stroke*. **2001**, 32, 2131-2136. doi: 10.1161/hs0901.094253.

[24] Medicover Hospitals, 2021. What is the life expectancy after a brain stroke? Available in: https://www.medicoverhospitals.in/what-is-the-life-expectancy-after-a-brain-stroke/. Accessed in August 26, **2021**.

[25] Petty, G.W.; Brown, R.D. Jr.; Whisnant, J.P.; Sicks, J.D.; O’Fallon, W.M.; Wiebers, D.O. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. *Neurology*. **1998**, 50, 208-16. doi: 10.1212/wnl.50.1.208.

[26] Vernino, S.; Brown Jr, R.D.; Sejvar, J.J.; Sicks, J.D.; Petty, G.W.; O’Fallon, W.M. Cause specific mortality after first cerebral infarction: a population-based study. *Stroke*. **2003**, 34, 1828–1832.

[27] Koton, S.; Tanne, D.; Green, M.S.; Bornstein, N.M. Mortality and predictors of death 1 month and 3 years after first-ever ischemic stroke: data from the first national acute stroke Israeli survey (NASIS 2004). *Neuroepidemiology*. **2010**, 34,90-6. doi: 10.1159/000264826.

[28] Jia, Q.; Liu, G.; Zheng, H.; Zhao, X.; Wang, C.; Wang, Y.; et al. Impaired Glucose Regulation Predicted 1-Year Mortality of Chinese Patients With Ischemic Stroke: Data From Abnormal Glucose Regulation in Patients With Acute Stroke Across China. *Stroke*. **2014**, 45, 1498-1500.
[29] Tziomalos, K.; Spanou, M.; Bouziana, S.D.; Papadopoulou, M.; Giampatzis, V.; Kostaki, S.; et al. Type 2 diabetes is associated with a worse functional outcome of ischemic stroke. *World J Diabetes*. 2014, 5, 939-944.

[30] Carter, A.M.; Catto, A.J.; Bamford, J.M.; Grant, P.J. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. *Arterioscler Thromb Vasc Biol*. 1998, 18, 1124-31. doi: 10.1161/01.atv.18.7.1124

[31] Hoekstra, T.; Geleijnse, J.M.; Kluft, C.; Giltay, E.J.; Kok, F.J.; Schouten, E.G. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. *Stroke*. 2003, 34, 2822–2828

[32] Reiner, A.P.; Carty, C.L.; Jenny, N.S.; Nievergelt, C.; Cushman, M.; Stearns-Kurosawa, D.J.; Kurosawa, S.; Kuller, L.H.; Lange, L.A. PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study. *J Thromb Haemost*. 2008, 6, 1625-32. doi: 10.1111/j.1538-7836.2008.03118.x.

[33] Trompet, S.; Pons, D.; Kanse, S.M.; de Craen, A.J.; Ikram, M.A.; Verschuren, J.J.; Zwinderman, A.H.; Doevedans, P.A.; Tio, R.A.; de Winter, R.J.; Slagboom, P.E.; Westendorp, R.G.; Jukema, J.W. Factor VII Activating Protease Polymorphism (G534E) Is Associated with
Increased Risk for Stroke and Mortality. *Stroke Res Treat*. **2011**, **2011**, 424759. doi: 10.4061/2011/424759.

[34] Lvy, W.; Lin, Y.; Song, W.; Sun, K.; Yu, H.; Zhang, Y.; Zhang, C.; Li, L.; Suo, M.; Hui, R.; Chen, J. Variants of COL3A1 are associated with the risk of stroke recurrence and prognosis in the Chinese population: a prospective study. *J Mol Neurosci*. **2014**, **53**, 196-203. doi: 10.1007/s12031-014-0283-x

[35] Martiskainen, M.; Oksala, N.; Pohjasvaara, T.; Kaste, M.; Oksala, A.; Karhunen, P.J.; Erkinjuntti, T. Beta-fibrinogen gene promoter A-455 allele associated with poor longterm survival among 55-71 years old Caucasian women in Finnish stroke cohort. *BMC Neurol*. **2014**, **14**, 137. doi: 10.1186/1471-2377-14-137.

[36] Shemirani, A.H.; Antalfi, B.; Pongrácz, E.; Mezei, Z.A.; Bereczky, Z.; Csiki, Z. Factor XIII-A subunit Val34Leu polymorphism in fatal atherothrombotic ischemic stroke. *Blood Coagul Fibrinolysis*. **2014**, **25**, 364–368. doi: 10.1097/MBC.0000000000000055.

[37] Bouziana, S.D.; Tziomalos, K.; Goulas, A.; Vyzantiadis, T.A.; Panderi, A.; Hatzitolios, A.I. Major Adipokines and the -420C>G Resistin Gene Polymorphism as Predictors of Acute Ischemic Stroke Severity and In-Hospital Outcome. *J Stroke Cerebrovasc Dis*. **2018**, **27**, 963-970. doi: 10.1016/j.jstrokecerebrovasdis.2017.10.038.
[38] Feng, C.; Yang, Y.; Yang, S.; Tu, X.; Wang, Y.; Song, Y.; Hui, R.; Zhang, W. Effect of gene-gene and gene-environment interaction on the risk of first-ever stroke and poststroke death. *Mol Genet Genomic Med.* **2019**, *7*, e846. doi: 10.1002/mgg3.846.

[39] Mola-Caminal, M.; Carrera, C.; Soriano-Tárraga, C.; Giralt-Steinhauer, E.; Díaz-Navarro, R.M.; Tur, S.; Jiménez, C.; et.al. PATJ Low Frequency Variants Are Associated with Worse Ischemic Stroke Functional Outcome. *Circ Res.* **2019**, *124*, 114-120. doi: 10.1161/CIRCRESAHA.118.313533

[40] Ryu, C.S.; Bae, J.; Kim, I.J.; Kim, J.; Oh, S.H.; Kim, O.J.; Kim, N.K. MPG and NPRL3 Polymorphisms are Associated with Ischemic Stroke Susceptibility and Post-Stroke Mortality. *Diagnostics (Basel).* **2020a**, *10*, 947. doi: 10.3390/diagnostics10110947.

[41] Ryu, C.S.; Oh, S.H.; Lee, K.O.; Park, H.S.; An, H.J.; Lee, J.Y.; Ko, E.J.; Park, H.W.; Kim, O.J.; Kim, N.K. MiR-10a, 27a, 34b/c, and 300 Polymorphisms are Associated with Ischemic Stroke Susceptibility and Post-Stroke Mortality. *Life (Basel).* **2020b**, *10*, 309. doi: 10.3390/life10120309.

[42] Song, L.; Li, H.; Suo, M.; Sun, Y.; Su, M.; Song, Y.; Xiao, N.; Hui, R.; Qin, C.; Chen, J. A functional variant of the long noncoding RNA AL110200 is associated with the risk of ischaemic stroke recurrence. *Eur J Neurol.* **2021**, *1*, doi: 10.1111/ene.14895.
[43] Banerjee, C.; Chimowitz, M.I. Stroke Caused by Atherosclerosis of the Major Intracranial Arteries. *Circ Res.* **2017**, *120*, 502–513.

[44] Jüttler, E.; Unterberg, A.; Woitzik, J.; Bösel, J.; Amiri, H.; Sakowitz, O.W.; Gondan, M.; Schiller, P.; Limprecht, R.; Luntz, S.; Schneider, H.; Pinzer, T.; Hobohm, C.; Meixensberger, J.; Hacke, W.; DESTINY II Investigators. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. *N Engl J Med.* **2014**, *370*, 1091-100. doi: 10.1056/NEJMoa1311367.

[45] Norrving, B.; Barrick, J.; Davalos, A.; Dichgans, M.; Cordonnier, C.; Guekht, A.; Kutluk, K.; Mikulik, R.; Wardlaw, J.; Richard, E.; Nabavi, D.; Molina, C.; Bath, P.M.; Stibrant Sunnerhagen, K.; Rudd, A.; Drummond, A.; Planas, A.; Caso, V. Action Plan for Stroke in Europe 2018-2030. *Eur Stroke J.* **2018**, *3*, 309-336. doi: 10.1177/2396987318808719.

[46] Zhou, S.; Liu, S.; Liu, X.; Zhuang, W. Bioinformatics Gene Analysis of Potential Biomarkers and Therapeutic Targets for Unstable Atherosclerotic Plaque-Related Stroke. *J Mol Neurosci.* **2021**, *71*, 1031-1045. doi: 10.1007/s12031-020-01725-2.

[47] Mussbacher, M.; Salzmann, M.; Brostjan, C.; Hoesel, B.; Schoergenhofer, C.; Datler, H.; Hohensinner, P.; Basilio, J.; Petzelbauer, P.; Assinger, A.; Schmid, J.A. Cell Type-Specific Roles of NF-κB Linking Inflammation and Thrombosis. *Front Immunol.* **2019**, *10*, :85. doi: 10.3389/fimmu.2019.00085.
[48] Harari, O.A.; Liao, J.K. NF-κB and innate immunity in ischemic stroke. *Ann N Y Acad Sci.* **2010**, 1207, 32-40. doi: 10.1111/j.1749-6632.2010.05735.x.

[49] Steffen, B.J.; Breier, G.; Butcher, E.C.; Schulz, M.; Engelhardt, B. ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. *Am J Pathol.* **1996**, 148, 1819–1838.

[50] Tang, S.C.; Arumugam, T.V.; Xu, X.; Cheng, A.; Mughal, M.R.; Jo, D.G.; Lathia, J.D.; Siler, D.A.; Chigurupati, S.; Ouyang, X.; Magnus, T.; Camandola, S.; Mattson, M.P. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. *Proc Natl Acad Sci USA.* **2007**, 104, 13798–13803

[51] Nurmi, A.; Lindsberg, P.J.; Koistinaho, M.; Zhang, W.; Juettler, E.; Karjalainen-Lindsberg, M.L.; Weih, F.; Frank, N.; Schwaninger, M.; Koistinaho, J. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. *Stroke.* **2004**, 35, 987-91. doi: 10.1161/01.STR.0000120732.45951.26

[52] Ali, A.; Shah, F.A.; Zeb, A.; Malik, I.; Alvi, A.M.; Alkury, L.T.; Rashid, S.; Hussain, I.; Ullah, N.; Khan, A.U.; Koh, P.O.; Li, S. NF-κB Inhibitors Attenuate MCAO Induced Neurodegeneration and Oxidative Stress-A Reprofiling Approach. *Front Mol Neurosci.* **2020**, 13, 33. doi: 10.3389/fnmol.2020.00033.
[53] Kim, S.K.; Jang, H.M.; Kimm D.Y. The promoter polymorphism of \textit{NFKB1} gene contributes to susceptibility of ischemic stroke in Korean population. \textit{J Exer Rehabil}. \textbf{2018}, 14, 1096-1100. doi: 10.12965/jer.1836592.296.

[54] Lanzillotta, A.; Sarnico, I.; Ingrassia, R.; Boroni, F.; Branca, C.; Benarese, M.; Faraco, G.; Blasi, F.; Chiarugi, A.; Spano, P.; Pizzi, M. The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury. \textit{Cell Death Dis}. \textbf{2010}, 1, e96. doi: 10.1038/cddis.2010.76. Erratum in: \textit{Cell Death Dis}. \textbf{2010}, 1, e107.

[55] Inta, I.; Paxian, S.; Maegele, I.; Zhang, W.; Pizzi, M.; Spano, P.; Sarnico, I.; Muhammad, S.; Herrmann, O.; Inta, D.; Baumann, B.; Liou, H.C.; Schmid, R.M.; Schwaninger, M.; Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. \textit{J Neurosci}. \textbf{2006}, 26, 12896-903. doi: 10.1523/JNEUROSCI.3670-06.2006.

[56] Tajalli-Nezhad, S.; Karimian, M.; Beyer, C.; Atlasi, M.A.; Azami Tameh, A. The regulatory role of Toll-like receptors after ischemic stroke: neurosteroids as TLR modulators with the focus on TLR2/4. \textit{Cell Mol Life Sci}. \textbf{2019}, 76, 523-537. doi: 10.1007/s00018-018-2953-2.

[57] Brea, D.; Blanco, M.; Ramos-Cabrera, P.; Moldes, O.; Arias, S.; Pérez-Mato, M.; Leira, R.; Sobrino, T.; Castillo, J. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. \textit{J Cereb Blood Flow Metab}. \textbf{2011}, 31,1424-31. doi: 10.1038/jcbfm.2010.231.
[58] Cao, C.X.; Yang, Q.W.; Lv, F.L.; Cui, J.; Fu, H.B.; Wang, J.Z. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. *Biochem Biophys Res Commun.* **2007**, *353*, 509-14. doi: 10.1016/j.bbrc.2006.12.057.

[59] Caso, J.R.; Pradillo, J.M.; Hurtado, O.; Leza, J.C.; Moro, M.A.; Lizasoain, I. Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. *Stroke.* **2008**, *39*, 1314-1320. doi: 10.1161/STROKEAHA.107.498212.

[60] Kawai, T.; Akira, S. Signaling to NF-kappaB by Toll-like receptors. *Trends Mol Med.* **2007**, *13*, 460-469. doi: 10.1016/j.molmed.2007.09.002.

[61] Lin, Y.C.; Chang, Y.M.; Yu, J.M.; Yen, J.H.; Chang, J.G.; Hu, C.J. Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. *Atherosclerosis.* **2005**, *180*, 305-9. doi: 10.1016/j.atherosclerosis.2004.12.022.

[62] Zaremba, J.; Losy, J. Early TNF-alpha levels correlate with ischaemic stroke severity. *Acta Neurol Scand.* 2001, **104**, 288-95. doi: 10.1034/j.1600-0404.2001.00053.x.

[63] Doll, D.N.; Rellick, S.L.; Barr, T.L.; Ren, X.; Simpkins, J.W. Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity. *J Neurochem.* **2015**, *132*, 443-451. doi: 10.1111/jnc.13008.
[64] Wu, J.C.; Zhang, X.; Wang, J.H.; Liu, Q.W.; Wang, X.Q.; Wu, Z.Q.; Wang, J.; Zhang, C.; Qun, S. Gene polymorphisms and circulating levels of the TNF-alpha are associated with ischemic stroke: A meta-analysis based on 19,873 individuals. *Int Immunopharmacol.* **2019**, *75*, 105827. doi: 10.1016/j.intimp.2019.105827.

[65] Tian, J.; Bai, Y.; You, A.; Shen, R.; Yan, J.; Deng, W.; Wen, L.; Li, M.; Teng, J. Interleukin-17 receptor C gene polymorphism reduces treatment effect and promotes poor prognosis of ischemic stroke. *Biosci Rep.* **2019**, *39*, BSR20190435. doi: 10.1042/BSR20190435. Erratum in: *Biosci Rep.* **2020**, *40*, BSR-20190435_COR. doi: 10.1042/BSR-20190435_COR.

[66] Zhang, Q.; Liao, Y.; Liu, Z.; Dai, Y.; Li, Y.; Li, Y.; Tang, Y. Interleukin-17 and ischaemic stroke. *Immunology.* **2021**, *162*, 179-193. doi: 10.1111/imm.13265.

[67] Planas, A. M.; Soriano, M. A.; Berruezo, M.; Justicia, C.; Estrada, A.; Pitarch, S.; Ferrer, I. Induction of Stat3, a signal transducer and transcription factor, in reactive microglia following transient focal cerebral ischaemia. *Eur. J. Neurosci.* **1996**, *8*, 2612–2618.

[68] Suzuki, S.; Tanaka, K.; Nogawa, S.; Dembo, T.; Kosakai, A.; Fukuuchi, Y. Phosphorylation of signal transducer and activator of transcription-3 (Stat3) after focal cerebral ischemia in rats. *Exp. Neurol.* **2001**, *170*, 63–71.

[69] Choi, J.S.; Kim, S.Y.; Cha, J.H.; Choi, Y.S.; Sung, K.W.; Oh, S.T.; Kim, O.N.; Chung, J.W.; Chun, M.H.; Lee, S.B.; Lee, M.Y. Upregulation of gp130 and STAT3 activation in the rat
hippocampus following transient forebrain ischemia. *Glia*. **2003**, 41, 237-46. doi: 10.1002/glia.10186.

[70] Satriotomo, I.; Bowen, K.K.; Vemuganti, R. JAK2 and STAT3 activation contributes to neuronal damage following transient focal cerebral ischemia. *J Neurochem*. **2006**, 98, 1353-68. doi: 10.1111/j.1471-4159.2006.04051.x.

[71] Wu, Y.; Xu, J.; Xu, J.; Zheng, W.; Chen, Q.; Jiao, D. Study on the mechanism of JAK2/STAT3 signaling pathway-mediated inflammatory reaction after cerebral ischemia. *Mol Med Rep*. **2018**, 17, 5007-5012. doi: 10.3892/mmr.2018.8477.

[72] Wang, X.L.; Qiao, C.M.; Liu, J.O.; Li, C.Y. Inhibition of the SOCS1-JAK2-STAT3 Signaling Pathway Confers Neuroprotection in Rats with Ischemic Stroke. *Cell Physiol Biochem*. **2017**, 44, 85-98. doi: 10.1159/000484585

[73] Morris, R.; Kershaw, N.J.; Babon, J.J. The molecular details of cytokine signaling via the JAK/STAT pathway. *Protein Sci*. **2018**, 27, 1984-2009. doi: 10.1002/pro.3519.

[74] Geddes, K.; Magalhães, J.G.; Girardin, S.E. Unleashing the therapeutic potential of NOD-like receptors. *Nat Rev Drug Discov*. **2009**, 8, 465-79. doi: 10.1038/nrd2783.

[75] Liu, H.; Wei, X.; Kong, L.; Liu, X.; Cheng, L.; Yan, S.; Zhang, X.; Chen, L. NOD2 is involved in the inflammatory response after cerebral ischemia-reperfusion injury and triggers NADPH
oxidase 2-derived reactive oxygen species. *Int J Biol Sci*. **2015**, 11, 525-35. doi: 10.7150/ijbs.10927.

[76] Vila, N.; Castillo, J.; Davalos, A.; Chamorro, A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. *Stroke*. **2000**, 31, 2325–9.

[77] Lv, K.; Yang, Y. Relationship between interleukin-10 polymorphisms and susceptibility to ischemic stroke: a Meta-analysis. *Scand J Clin Lab Invest*. **2020**, 80, 20-24. doi: 10.1080/00365513.2019.1689427.

[78] Zhao, X.; Wang, H.; Sun, G.; Zhang, J.; Edwards, N.J.; Aronowski, J. Neuronal Interleukin-4 as a Modulator of Microglial Pathways and Ischemic Brain Damage. *J Neurosci*. **2015**, 35, 11281-91. doi: 10.1523/JNEUROSCI.1685-15.2015.

[79] Xiong, X.; Barreto, G.E.; Xu, L.; Ouyang, Y.B.; Xie, X.; Giffard, R.G. Increased brain injury and worsened neurological outcome in interleukin-4 knockout mice after transient focal cerebral ischemia. *Stroke*. **2011**, 42, 2026-32. doi: 10.1161/STROKEAHA.110.593772.

[80] Hamzei Taj, S.; Le Blon, D.; Hoornaert, C.; Daans, J.; Quarta, A.; Praet, J.; Van der Linden, A.; Ponsaerts, P.; Hoehn, M. Targeted intracerebral delivery of the anti-inflammatory cytokine IL13 promotes alternative activation of both microglia and macrophages after stroke. *J Neuroinflammation*. **2018**, 15, 174. doi: 10.1186/s12974-018-1212-7.
[81] Couper, K.N.; Blount, D.G.; Riley, E.M. IL-10: the master regulator of immunity to infection. 
*J Immunol*. **2008**, 180, 5771-7. doi: 10.4049/jimmunol.180.9.5771.

[82] Pera, J.; Zawadzka, M.; Kaminska, B.; Szczudlik, A. Influence of chemical and ischemic preconditioning on cytokine expression after focal brain ischemia. *J Neurosci Res*. **2004**, 78, 132-40. doi: 10.1002/jnr.20232

[83] Bonni, S.; Bonni, A. SnoN signaling in proliferating cells and postmitotic neurons. *FEBS Lett*. **2012**, 586, 1977-1983. doi: 10.1016/j.febslet.2012.02.048.

[84] Caraci, F.; Battaglia, G.; Sortino, M.A.; Spampinato, S.; Molinaro, G.; Copani, A.; Nicoletti, F.; Bruno, V. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic? *Neurochem Int*. **2012**, 61, 559-65. doi: 10.1016/j.neuint.2012.01.017

[85] Kumar, P.; Misra, S.; Kumar, A.; Faruq, M.; Shakya, S.; Vardhan, G.; Vivekanandhan, S.; Srivastava, A.K.; Prasad, K. Transforming growth factor-β1 (C509T, G800A, and T869C) gene polymorphisms and risk of ischemic stroke in North Indian population: A hospital-based case-control study. *Ann Indian Acad Neurol*. **2017**, 20, 5-12. doi: 10.4103/0972-2327.199910.

[86] Konkel, J.E.; Chen. W. Balancing acts: the role of TGF-β in the mucosal immune system. *Trends Mol Med*. **2011**, 17, 668-76. doi: 10.1016/j.molmed.2011.07.002.
[87] Kovacic, P.; Somanathan, R. Cell signaling and receptors in toxicity of advanced glycation end products (AGEs): α-dicarbonyls, radicals, oxidative stress and antioxidants. *J Recept Signal Transduct Res.* 2011, 31, 332-9. doi: 10.3109/10799893.2011.607171.

[88] Liu, F.F.; Liu, C.Y.; Li, X.P.; Zheng, S.Z.; Li, Q.Q.; Liu, Q.; Song, L. Neuroprotective effects of SMADs in a rat model of cerebral ischemia/reperfusion. *Neural Regen Res.* 2015, 10, 438-44. doi: 10.4103/1673-5374.153693.

[89] Zhu, H.; Gui, Q.; Hui, X.; Wang, X.; Jiang, J.; Ding, L.; Sun, X.; Wang, Y.; Chen, H. TGF-β1/Smad3 Signaling Pathway Suppresses Cell Apoptosis in Cerebral Ischemic Stroke Rats. *Med Sci Monit.* 2017, 23, 366-376. doi: 10.12659/msm.899195.

[90] Supanc, V.; Biloglav, Z.; Kes, V.B.; Demarin, V. Role of cell adhesion molecules in acute ischemic stroke. *Ann Saudi Med.* 2011, 31, 365-70. doi: 10.4103/0256-4947.83217.

[91] Kong, D.H.; Kim, Y.K.; Kim, M.R.; Jang, J.H.; Lee, S. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. *Int J Mol Sci.* 2018, 19, 1057. doi: 10.3390/ijms19041057.

[92] Kivisäkk, P.; Mahad, D.J.; Callahan, M.K.; Trebst, C.; Tucky, B.; Wei, T.; Wu, L.; Baekkevold, E.S.; Lassmann, H.; Staugaitis, S.M.; Campbell, J.J.; Ransohoff, R.M. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus
and meninges via P-selectin. *Proc Natl Acad Sci U S A.* 2003, 100, 8389-94. doi: 10.1073/pnas.1433000100.

[93] Maglinger, B.; Sands, M.; Frank, J.A.; McLouth, C.J.; Trout, A.L.; Roberts, J.M.; Grupke, S.; Turchan-Cholewo, J.; Stowe, A.M.; Fraser, J.F.; Pennypacker, K.R. Intracranial VCAM1 at time of mechanical thrombectomy predicts ischemic stroke severity. *J Neuroinflammation.* 2021, 18, 109. doi: 10.1186/s12974-021-02157-4. PMID: 33971895;

[94] Frijns, C.J.; Kappelle, LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. *Stroke.* 2002, 33, 2115-22. doi: 10.1161/01.str.0000021902.33129.69

[95] Castillo, J.; Alvarez-Sabín, J.; Martínez-Vila, E.; Montaner, J.; Sobrino T.; Vivancos, J.; MITICO Study Investigators. Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. *J Neurol.* 2009, 256, 217-24. doi: 10.1007/s00415-009-0058-4.

[96] Levine, S.R.; Brey, R.L.; Tilley, B.C.; et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. *JAMA.* 2004, 291,576–584.

[97] Bushnell, C.; Siddiqi, Z.; Morgenlander, J.; Goldstein, L. Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. *Neurology.* 2001, 56, 624–627.

[98] Bushnell, C.; Siddiqi, Z.; Goldstein, L. Improving patient selection for coagulopathy testing in the setting of acute ischemic stroke. *Neurology.* 2001, 57, 1333–1335.
[99] Patel, M.L.; Sachan, R.; Seth, G. Combined deficiency of proteins C and S: ischaemic stroke in young individuals. *BMJ Case Rep.* **2013**, 2013, bcr2012008016. doi: 10.1136/bcr-2012-008016

[100] Luo, G.P.; Ni, B.; Yang, X.; Wu, Y.Z. von Willebrand factor: more than a regulator of hemostasis and thrombosis. *Acta Haematol.* **2012**, 128, 158-69. doi: 10.1159/000339426

[101] Gragnano, F.; Sperlongano, S.; Golia, E.; Natale, F.; Bianchi, R.; Crisci, M.; et al. The role of von willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. *Mediators Inflamm.* **2017**, 2017, 5620314. doi: 10.1155/2017/5620314

[102] Sidelmann, J.J.; Gram, J.; Jespersen, J.; Kluft, C. Fibrin clot formation and lysis: basic mechanisms. *Semin Thromb Hemost.* **2000**, 26, 605–18. doi: 10.1055/s-2000-13216

[103] Kozuka, K.; Kohriyama, T.; Ikeda, J.; Nakamura, S.; Nomura, E.; Kajikawa, H. Endothelial markers and adhesion molecules in acute ischemic stroke- Sequential change and differences in stroke subtype. *Atherosclerosis.* **2002**, 161, 161–168. doi: 10.1016/S0021-9150(01)00635-9

[104] Hanson, E.; Jood, K.; Karlsson, S.; Nilsson, S.; Blomstrand, C.; Jern, C. Plasma levels of vonWillebrand factor in the etiologic subtypes of ischemic stroke. *J Thromb Haemost.* **2011**, 9, 275–81. doi: 10.1111/j.1538-7836.2010.04134.x
[105] Ancedy, Y.; Berthelot, E.; Lang, S.; Ederhy, S.; Boyer-Chatenet, L.; Di Angelantonio, E.; et al. Is vonWillebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation? *Arch Cardiovasc Dis.* 2018, 111, 357–69. doi: 10.1016/j.acvd.2017.08.004

[106] Tóth, N.K.; Székely, E.G.; Czuriga-Kovács, K.R.; Sarkady, F.; Nagy, O.; Lánczi, L.I.; et al. Elevated factor VIII and vonWillebrand factor levels predict unfavorable outcome in stroke patients treated with intravenous thrombolysis. *Front Neurol.* 2018, 8, 721. doi: 10.3389/fneur.2017.00721

[107] Schuppner, R.; Dirks, M.; Grosse, G.M.; Böckmann, M.; Goetz, F.; Pasedag, T.; et al. ADAMTS-13 activity predicts outcome in acute ischaemic stroke patients undergoing endovascular treatment. *Thromb Haemost.* 2018, 118, 758–67. doi: 10.1055/s-0038-1637732

[108] Dai, K.; Gao, W.; Ruan, C. The Sma I polymorphism in the von Willebrand factor gene associated with acute ischemic stroke. *Thromb Res.* 2001, 104, 389-95. doi: 10.1016/s0049-3848(01)00389-9.

[109] De Meyer, S.F.; Stoll, G.; Wagner, D.D.; Kleinschnitz, C. von Willebrand factor: an emerging target in stroke therapy. *Stroke.* 2012, 43, 599-606. doi: 10.1161/STROKEAHA.111.628867
[110] Drouet, L. Fibrinogen: a treatable risk factor? Cerebrovasc Dis. 1996, 6, 2–6. doi.org/10.1159/000108065

[111] Pieters, M.; Wolberg, A.S. Fibrinogen and fibrin: an illustrated review. Res Pract Thromb Haemost. 2019, 3, 161–172. doi: 10.1002/rth2.12191

[112] Rallidis, L.S.; Vikelis, M.; Panagiotakos, D.B.; Liakos, G.K.; Krania, E.; Kremastinos, D.T. Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle-aged ischaemic stroke patients. Acta Neurol Scand. 2008, 117, 415-20. doi: 10.1111/j.1600-0404.2007.00971.x.

[113] Swarowska, M.; Polczak, A.; Pera, J.; Klimkowicz-Mrowiec, A.; Slowik, A.; Dziedzic, T. Hyperfibrinogenemia predicts long-term risk of death after ischemic stroke. J Thromb Thrombolysis. 2014, 38, 517-21. doi: 10.1007/s11239-014-1122-1.

[114] Di Napoli, M.; Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke. 2002, 33, 763–71. doi: 10.1161/01.STR.0000019124.54361.08

[115] Pikija, S.; Trkulja, V.; Mutzenbach, J.S.; McCoy, M.R.; Ganger, P.; Sellner, J. Fibrinogen consumption is related to intracranial clot burden in acute ischemic stroke: a retrospective hyperdense artery study. J Transl Med. 2016, 14, 1–9. doi: 10.1186/s12967-016-1006-6
[116] Beamer, N.B.; Coull, B.M.; Clark, W.M.; Hazel, J.S.; Silberger, J.R. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. *Ann. Neurol.* **1995**, *37*, 800–805.

[117] Di Napoli, M.; Papa, F.; Bocola, V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. *Stroke.* **2001**, *32*, 133–138.

[118] Di Napoli, M.; Singh, P. Is plasma fibrinogen useful in evaluating ischemic stroke patients? Why, how, and when. *Stroke.* **2009**, *40*, 1549–1552.

[119] Feinberg, W.M.; Erickson, L.P.; Bruck, D.; Kittelson, J. Hemostatic markers in acute ischemic stroke. association with stroke type, severity, and outcome. *Stroke.* **1996**, *27*, 1296–1300.

[120] Barber, M.; Langhorne, P.; Rumley, A.; Lowe, G.D.; Stott, D.J. D-dimer predicts early clinical progression. *Stroke.* **2004**, *35*, 1421–1425.

[121] Carter, A.M.; Catto, A.J.; Mansfield, M.W.; Bamford, J.M.; Grant, P.J. Predictive variables for mortality after acute ischemic stroke. *Stroke.* **2007**, *38*, 1873–1880.

[122] Ribó, M.; Montaner, J.; Molina, C.A.; Arenillas, J.F.; Santamarina, E.; Alvarez-Sabín, J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. *Thromb. Haemost.* **2004**, *91*, 1146–1151.
[123] Merino, P.; Diaz, A.; Yepes, M. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain. Receptors Clin Investig. 2017, 4, e1552.

[124] Diaz, A.; Merino, P.; Manrique, L.G.; Cheng, L.; Yepes, M. Urokinase-type plasminogen activator (uPA) protects the tripartite synapse in the ischemic brain via ezrin-mediated formation of peripheral astrocytic processes. J Cereb Blood Flow Metab. 2019, 39, 2157-2171. doi: 10.1177/0271678X18783653

[125] Menshikov, M.; Plekhanova, O.; Cai, H.; Chalupsky, K.; Parfyonova, Y.; Bashtrikov, P.; Tkachuk, V.; Berk, B.C. Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox-dependent pathways. Arterioscler Thromb Vasc Biol. 2006, 26, 801-7. doi: 10.1161/01.ATV.0000207277.27432.15.

[126] Kim, S.H.; Turnbull, J.; Guimond, S. Extracellular matrix and cell signaling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol. 2011, 209, 139-51. doi: 10.1530/JOE-10-0377.

[127] Guell, K.; Bix, G.J. Brain endothelial cell specific integrins and ischemic stroke. Expert Rev Neurother. 2014, 14, 1287-92. doi: 10.1586/14737175.2014.964210.

[128] Edwards, D.N.; Bix, G.J. Roles of blood-brain barrier integrins and extracellular matrix in stroke. Am J Physiol Cell Physiol. 2019, 316, C252-C263. doi: 10.1152/ajpcell.00151.2018
[129] Edwards, D.N.; Bix, G.J. The Inflammatory Response After Ischemic Stroke: Targeting β₂ and β₁ Integrins. *Front Neurosci.* **2019**, **13**, 540. doi: 10.3389/fnins.2019.00540.

[130] Baeten, K.M.; Akassoglou, K. Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. *Dev Neurobiol.* **2011**, **71**, 1018-1039. doi: 10.1002/dneu.20954.

[131] Yang, C.; Hawkins, K.E.; Doré, S.; Candelario-Jalil, E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. *Am J Physiol Cell Physiol.* **2019**, **316**, C135-C153. doi: 10.1152/ajpcell.00136.2018.

[132] Kusindarta D, Wihadmadyatami H. The Role of Extracellular Matrix in Tissue Regeneration. IntechOpen Book Series. Open access peer-reviewed paper. 2018. DOI: 10.5772/intechopen.75728. The Role of Extracellular Matrix in Tissue Regeneration | IntechOpen. Available from: https://www.intechopen.com/chapters/60312.

[133] Paar, M.; Rossmann, C.; Nusshold, C.; Wagner, T.; Schlagenhauf, A.; Leschnik, B.; Oettl, K.; Koestenberger, M.; Cvirn, G.; Hallström, S. Anticoagulant action of low, physiologic, and high albumin levels in whole blood. *PLoS One.* **2017**, **12**, e0182997. doi: 10.1371/journal.pone.0182997.

[134] Rogers, K. Serum Albumin. Encyclopaedia Britannica. Published 23-11-2018. As accessed 30-8-2021. [www.britannica.com](http://www.britannica.com/science/serum-albumin)
[135] Greenberg, D.A.; Jin, K. Vascular endothelial growth factors (VEGFs) and stroke. *Cell Mol Life Sci.* **2013**, *70*, 1753-1761. doi: 10.1007/s00018-013-1282-8.

[136] Kim, O.J.; Hong, S.H.; Oh, S.H.; Ki, T.G.; Min, K.T.; Oh, D.; Kim, N.K. Association between VEGF polymorphisms and homocysteine levels in patients with ischemic stroke and silent brain infarction. *Stroke.* **2011**, *42*, 2393-402. doi: 10.1161/STROKEAHA.110.607739.

[137] Vallance, T.M.; Zeuner, M.T.; Williams, H.F.; Widera, D.; Vaiyapuri, S. Toll-Like Receptor 4 Signalling and Its Impact on Platelet Function, Thrombosis, and Haemostasis. *Mediators Inflamm.* **2017**, *2017*, 9605894. doi: 10.1155/2017/9605894

[138] Zhang, S.; Zhang, S.; Hu, L.; Zhai, L.; Xue, R.; Ye, J.; Chen, L.; Cheng, G.; Mruk, J.; Kunapuli, S.P.; Ding, Z. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis. *Circulation.* **2015**, *131*, 1160-70. doi: 10.1161/CIRCULATIONAHA.114.013743

[139] Van der Poll, T.; Jansen, P.M.; Van Zee, K.J.; Welborn, M.B. 3rd.; de Jong, I.; Hack, C.E.; Loetscher, H.; Lesslauer, W.; Lowry, S.F.; Moldawer, L.L. Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. *Blood.* **1996**, *88*, 922-7.
[140] Fateh-Moghadam, S.; Li, Z.; Ersel, S.; Reuter, T.; Htun, P.; Plöckinger, U.; Bocksch, W.; Dietz, R.; Gawaz, M. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. *Arterioscler Thromb Vasc Biol.* 2005, 25, 1299-303. doi: 10.1161/01.ATV.0000165699.41301.c5.

[141] Foley, J.H.; Conway, E.M. Cross Talk Pathways Between Coagulation and Inflammation. *Circ Res.* 2016, 118, 1392-408. doi: 10.1161/CIRCRESAHA.116.306853

[142] Ma, S.; Snyder, M.; Dinesh-Kumar, S.P. Discovery of Novel Human Gene Regulatory Modules from Gene Co-expression and Promoter Motif Analysis. *Sci Rep.* 2017, 7, 5557. doi: 10.1038/s41598-017-05705-2.

[143] DeGracia, D.J. Regulation of mRNA following brain ischemia and reperfusion. *Wiley Interdiscip Rev RNA.* 2017, 8, doi: 10.1002/wrna.1415.

[144] DeGracia, D.J. Disease of mRNA Regulation: Relevance for Ischemic Brain Injury. *Transl Stroke Res.* 2018, 9, 251-257. doi: 10.1007/s12975-017-0586-7

[145] Khajavi, M.; Inoue, K.; Lupski, J.R. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. *Eur J Hum Genet.* 2006, 14, 1074-81. doi: 10.1038/sj.ejhg.5201649.
[146] Gu, Z.; Li, Z.; Xu, R.; Zhu, X.; Hu, R.; Xue, Y.; Xu, W. miR-16-5p Suppresses Progression and Invasion of Osteosarcoma via Targeting at Smad3. *Front Pharmacol.* **2020**, *26*, 11:1324. doi: 10.3389/fphar.2020.01324.

[147] Zhou, R.; Li, X.; Hu, G.; Gong, A.Y.; Drescher, K.M.; Chen, X.M. miR-16 targets transcriptional corepressor SMRT and modulates NF-kappaB-regulated transactivation of interleukin-8 gene. *PLoS One*. **2012**, *7*, e30772. doi: 10.1371/journal.pone.0030772.

[148] Xu, H.; Zhang, J.; Ma, Y.; Gu, J.; Jing, X.; Lu, S.; Chen, X.; Yang, W.; Bian, Y.; Fu, S. The Identification and Verification of Key Long Noncoding RNAs in Ischemic Stroke. *Biomed Res Int*. **2020**, 2020, 2094320. doi: 10.1155/2020/2094320.

[149] Su, Z.F.; Sun, Z.W.; Zhang, Y.; Wang, S.; Yu, Q.G.; Wu, Z.B. Regulatory effects of miR-146a/b on the function of endothelial progenitor cells in acute ischemic stroke in mice. *Kaohsiung J Med Sci*. **2017**, *33*, 369-378. doi: 10.1016/j.kjms.2017.05.010

[150] Koutsis, G.; Siasos, G.; Spengos, K. The emerging role of microRNA in stroke. *Curr Top Med Chem.* 2013, *13*, 1573-88. doi: 10.2174/1568026613139990106.

[151] Wu, J.; Du, K.; Lu, X. Elevated expressions of serum miR-15a, miR-16, and miR-17-5p are associated with acute ischemic stroke. *Int J Clin Exp Med*. **2015**, *8*, 21071-9
[152] Reiche, E.M.V.; Gelinski, J.R.; Alfieri, D.F.; Flauzino, T.; Lehmann, M.F.; de Araújo, M.C.M.; Lozovoy, M.A.B.; Simão, A.N.C.; de Almeida, E.R.D.; Maes, M. Immune-inflammatory, oxidative stress and biochemical biomarkers predict short-term acute ischemic stroke death. *Metab Brain Dis.* **2019**, *34*, 789-804. doi: 10.1007/s11011-019-00403-6.

[153] Maes, M.; Plaimas, K.; Suratanee, A.; Noto, C.; Kanchanatawan, B. The Protein-Protein Interaction Network of First Episode Psychosis and Schizophrenia Reveals Possible Trigger Factors and New Drug Targets among Intracellular Signal Transduction Pathways and Neurotoxicity Processes. *Preprints 2021*, 2021070596 (doi: 10.20944/preprints202107.0596.v1).

[154] Martin, R.H.; Yeatts, S.D.; Hill MD, Moy CS, Ginsberg MD, Palesch YY; ALIAS Parts 1 and 2 and NETT Investigators. ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2. *Stroke*. **2016**, *47*, 2355-9. doi: 10.1161/STROKEAHA.116.012825.

[155] Bae, O.N. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk. *Arch Pharm Res*. **2012**, *35*, 1693-16999. doi: 10.1007/s12272-012-1000-3.

[156] Drakeford, C.; O'Donnell, J.S. Targeting von Willebrand Factor-Mediated Inflammation. *Arterioscler Thromb Vasc Biol*. **2017**, *37*, 1590-1591. doi: 10.1161/ATVBAHA.117.309817
[157] Buchtele, N.; Schwameis, M.; Gilbert, J.C.; Schörgenhofer, C.; Jilma, B. Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence. *Thromb Haemost*. **2018**, *118*, 959-978. doi: 10.1055/s-0038-1648251.

[158] Howell, J.A.; Bidwell, G.L. 3rd. Targeting the NF-κB pathway for therapy of ischemic stroke. *Ther Deliv*. **2020**, *11*, 113-123. doi: 10.4155/tde-2019-0075.
Table 1. Results of Molecular Complex Detection (MCODE) analysis performed on the differently expressed proteins (DEPs) of death due to ischemic stroke.

| MCODE Components | GO ID               | Biological term                                      | Log10 (p) |
|------------------|---------------------|------------------------------------------------------|-----------|
| All DEPs, MCODE1| R-HSA-449147        | Signaling by Interleukins                             | -42.1     |
|                  | GO:0006954          | Inflammatory response                                 | -40.9     |
|                  | ko04668             | Cytokine signaling in immune system                   | -40.1     |
| All DEPs, MCODE2| R-HSA-140877        | Formation of fibrin clot (Clotting Cascade)           | -19.4     |
|                  | R-HSA-140875        | Common pathway of fibrin clot formation                | -17.5     |
|                  | GO:0050819          | Negative regulation of coagulation                    | -15.1     |
| All DEPs, MCODE3| R-HSA-109582        | Hemostasis                                            | -6.6      |
|                  | GO:0007596          | Blood coagulation                                     | -5.1      |
|                  | GO:0007599          | Hemostasis                                            | -5.1      |
| Cluster 2 DEPs, MCODE2 | M174                | PID UPA UPAR PATHWAY                                  | -21.5     |
|                  | R-HSA-1566948       | Elastic fiber formation                               | -20.2     |
|                  | GO:0009611          | Response to wounding                                  | -20.2     |
| Cluster 2 DEPs, MCODE3 | GO:0043691         | Reverse cholesterol transport                         | -9.5      |
|                  | GO:0071827          | Plasma lipoprotein particle organization              | -8.5      |
|                  | GO:0071825          | Protein-lipid complex subunit organization            | -8.1      |
Table 2. REACTOME path classifications of the differently expressed proteins in cluster 1 of death due to stroke.

| Path ID      | Pathway names in cluster 1                                               | Found | Total | Ratio   | P value    | pFDR     |
|--------------|---------------------------------------------------------------------------|-------|-------|---------|------------|----------|
| R-HSA-5357956 | TNFR1-induced NFkappaB signaling pathway                                  | 11    | 30    | 0,002063| 1,11E-16   | 6,77E-15 |
| R-HSA-6783783 | Interleukin-10 signaling                                                  | 31    | 86    | 0,005914| 1,11E-16   | 6,77E-15 |
| R-HSA-6785807 | Interleukin-4 and interleukin-13 signaling                                | 28    | 211   | 0,01451 | 1,11E-16   | 6,77E-15 |
| R-HSA-449147 | Signaling by interleukins                                                 | 55    | 643   | 0,044217| 1,11E-16   | 6,77E-15 |
| R-HSA-1280215 | Cytokine signaling in immune system                                       | 62    | 1092  | 0,075093| 1,11E-16   | 6,77E-15 |
| R-HSA-168256 | Immune system                                                            | 67    | 2681  | 0,184363| 1,11E-16   | 6,77E-15 |
| R-HSA-75893  | TNF signaling                                                            | 11    | 51    | 0,003507| 1,67E-14   | 8,66E-13 |
| R-HSA-1059683| Interleukin-6 signaling                                                   | 8     | 17    | 0,001169| 1,55E-13   | 7,13E-12 |
| R-HSA-446652 | Interleukin-1 family signaling                                           | 14    | 167   | 0,011484| 1,23E-12   | 5,04E-11 |
| R-HSA-5357905| Regulation of TNFR1 signaling                                            | 9     | 41    | 0,002819| 3,82E-12   | 1,38E-10 |
| R-HSA-73887  | Death receptor signaling                                                  | 13    | 158   | 0,010865| 1,05E-11   | 3,46E-10 |
| R-HSA-6783589| Interleukin-6 family signaling                                           | 8     | 30    | 0,002063| 1,37E-11   | 4,11E-10 |
| R-HSA-168164 | Toll Like Receptor 3 (TLR3) cascade                                      | 10    | 102   | 0,007014| 5,59E-10   | 1,56E-08 |
| R-HSA-937061 | TRIF(TICAM1)-mediated TLR4 signaling                                     | 10    | 107   | 0,007358| 8,81E-10   | 2,11E-08 |

| Path ID      | Pathway names in cluster 2                                               | Found | Total | Ratio   | p          | pFDR     |
|--------------|---------------------------------------------------------------------------|-------|-------|---------|------------|----------|
| R-HSA-140875 | Common pathway of fibrin clot formation                                   | 16    | 25    | 0,001719| 1,11E-16   | 4,33E-15 |
| R-HSA-8957275| Post-translational protein phosphorylation                               | 17    | 109   | 0,007496| 1,11E-16   | 4,33E-15 |
| R-HSA-216083 | Integrin cell surface interactions                                       | 15    | 86    | 0,005914| 1,11E-16   | 4,33E-15 |
| R-HSA-140877 | Formation of fibrin clot (Clotting Cascade)                              | 24    | 43    | 0,002957| 1,11E-16   | 4,33E-15 |
| R-HSA-76009  | Platelet aggregation (Plug Formation)                                   | 13    | 53    | 0,003645| 1,11E-16   | 4,33E-15 |
| Ref          | Description                                                                 | FDR (adj) | TNFR1 | P-value   | FDR (adj) |
|--------------|------------------------------------------------------------------------------|-----------|-------|-----------|-----------|
| R-HSA-140837 | Intrinsic pathway of fibrin clot formation                                   | 0.001788  |       | 1.11E-16  | 4.33E-15  |
| R-HSA-109582 | Hemostasis                                                                   | 0.055082  |       | 1.11E-16  | 4.33E-15  |
| R-HSA-114608 | Platelet degranulation                                                       | 0.009559  |       | 1.11E-16  | 4.33E-15  |
| R-HSA-76002  | Platelet activation, signaling and aggregation                              | 0.020011  |       | 1.11E-16  | 4.33E-15  |
| R-HSA-76005  | Response to elevated platelet cytosolic Ca**2+**                            | 0.01004   |       | 1.11E-16  | 4.33E-15  |
| R-HSA-381426 | Regulation of insulin-like growth factor (IGF) transport and uptake by insulin-like growth factor binding proteins (IGFBPs) | 0.008733  |       | 1.11E-16  | 4.33E-15  |
| R-HSA-1566948| Elastic fiber formation                                                      | 0.003163  |       | 8.88E-16  | 3.20E-14  |
| R-HSA-2129379| Molecules associated with elastic fibers                                    | 0.002613  |       | 5.00E-15  | 1.65E-13  |

FDR: False Discovery Rate; TNFR1: tumor necrosis factor receptor 1; TNF: tumor necrosis factor; TRIF(TICAM1): Toll Like Receptor Adaptor Molecule 1.
Table 3. Results of Molecular Complex Detection (MCODE) analysis performed on differentially expressed proteins (DEPs) and genes of death due to ischemic stroke.

| MCODE Components | GO ID          | Biological term                        | Log10 (p) value |
|------------------|----------------|----------------------------------------|-----------------|
| All DEPs/genes, cluster 1, MCODE2 | R-HSA-3000178  | ECM proteoglycans                      | -7.1            |
|                   | WP306| Focal adhesion                          | -5.8            |
|                   | R-HSA-1474244 | Extracellular matrix organization      | -5.3            |
| All DEPs/genes, cluster 2, MCODE1 | ko04668 | TNF signaling pathway                   | -40.4           |
|                   | hsa04668 | TNF signaling pathway                   | -39.8           |
|                   | ko04657 | IL-17 signaling pathway                 | -28.7           |

GO ID: Gene Ontology Identification; ECM: extracellular matrix; TNF: tumor necrosis factor; IL: interleukin.
Table 4. KEGG pathway classifications of the differently expressed proteins and genes in cluster 1 and 2 of death due to stroke.

| Path ID  | Pathway names associated with Cluster 1 | Observed | background | Strength   | pFDR       |
|----------|----------------------------------------|----------|------------|------------|------------|
| hsa04610 | Complement and coagulation cascades    | 27       | 78         | 1.89       | 4.62E-39   |
| hsa04510 | Focal adhesion                         | 24       | 197        | 1.43       | 4.40E-25   |
| hsa05205 | Proteoglycans in cancer                | 23       | 195        | 1.42       | 7.70E-24   |
| hsa04151 | PI3K-Akt signaling pathway             | 25       | 348        | 1.2        | 3.09E-21   |
| hsa04611 | Platelet activation                    | 18       | 123        | 1.51       | 3.93E-20   |
| hsa04512 | ECM-receptor interaction               | 16       | 81         | 1.64       | 9.21E-20   |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 16       | 98         | 1.56       | 1.21E-18   |
| hsa04926 | Relaxin signaling pathway              | 16       | 130        | 1.44       | 6.38E-17   |
| hsa04810 | Regulation of actin cytoskeleton       | 14       | 205        | 1.18       | 9.32E-12   |
| hsa04068 | FoxO signaling pathway                 | 12       | 130        | 1.31       | 1.52E-11   |

| Path ID  | Pathway names associated with Cluster 2 | Observed | background | Strength   | pFDR       |
|----------|----------------------------------------|----------|------------|------------|------------|
| hsa04668 | TNF signaling pathway                  | 30       | 108        | 1.81       | 4.79E-42   |
| hsa04060 | Cytokine-cytokine receptor interaction | 35       | 263        | 1.49       | 5.35E-40   |
| hsa04620 | Toll-like receptor signaling pathway   | 23       | 102        | 1.72       | 3.08E-30   |
| hsa04657 | IL-17 signaling pathway                | 22       | 92         | 1.75       | 1.44E-29   |
| hsa04064 | NF-kappa B signaling pathway           | 22       | 93         | 1.74       | 1.48E-29   |
| hsa04621 | NOD-like receptor signaling pathway    | 25       | 166        | 1.55       | 1.84E-29   |
| hsa04630 | Jak-STAT signaling pathway             | 22       | 160        | 1.51       | 3.66E-25   |
| hsa04380 | Osteoclast differentiation             | 20       | 124        | 1.57       | 4.30E-24   |
| hsa04659 | Th17 cell differentiation              | 19       | 102        | 1.64       | 5.84E-24   |
| hsa04622 | RIG-I-like receptor signaling pathway  | 17       | 70         | 1.75       | 3.72E-23   |

KEGG: Kyoto Encyclopedia of Genes and Genomes; ID: Identification; FDR: False Discovery Rate; PI3K-Akt: Phosphatidylinositol 3-kinase-protein kinase B; ECM: extracellular matrix; AGE-RAGE: Advanced glycation end products and their receptors; TNF: tumor
necrosis factor; IL: interleukin; NF-kappa B: nuclear factor kappa B; NOD: nucleotide-binding, and oligomerization domain; Jak-STAT: Janus kinase -signal transducer and activator of transcription; Th: T helper; RIG: Retinoic acid-inducible gene.
Table 5. Results of inBio Discover annotation analysis with the DOID disease annotations classification in ischemic death to stroke proteins and genes.

| DOID ID    | Disease                                           | Size | Overlap | Enrichment | p-value  |
|------------|---------------------------------------------------|------|---------|------------|----------|
| DOID:0060032 | Autoimmune disease of the musculoskeletal system | 645  | 62/267  | 7.20       | 1.8E-35  |
| DOID:1247 | Blood coagulation disease                        | 238  | 42/267  | 13.22      | 7.3E-35  |
| DOID:612 | Primary immunodeficiency syndrome                 | 1.3k | 83/267  | 4.67       | 5.0E-34  |
| DOID:74 | Hematopoietic disease                            | 1.6k | 91/267  | 4.20       | 5.4E-34  |
| DOID:2349 | Atherosclerosis                                   | 363  | 48/247  | 9.90       | 9.4E-34  |
| DOID:7148 | Rheumatoid arthritis                             | 313  | 45/247  | 10.77      | 2.9E-33  |
| DOID:2348 | Atherosclerotic cardiovascular disease           | 352  | 47/247  | 10.00      | 3.0E-33  |
| DOID:417 | Autoimmune disease                               | 1.1k | 74/246  | 5.20       | 3.3E-33  |
| DOID:0060903 | Thrombosis                                   | 108  | 31/247  | 21.50      | 5.9E-33  |
| DOID:2941 | Immune system disease                            | 1.9k | 95/267  | 3.75       | 1.2E-31  |

DOID ID: Disease Ontology - Institute for Genome Sciences @ University of Maryland (disease-ontology.org)
Table 5. REACTOME pathways and PANTHER biological processes statistically over-represented in the DEPs/gene list of death due to stroke.

| REACTOME pathways                                      | Total | Expected | Hits | p        | pFDR     |
|--------------------------------------------------------|-------|----------|------|----------|----------|
| Metabolism of mRNA                                     | 317   | 30.3     | 95   | 4.15E-26 | 5.82E-23 |
| Metabolism of RNA                                      | 339   | 32.4     | 98   | 1.39E-25 | 9.73E-23 |
| 3’-UTR-mediated translational regulation               | 201   | 19.2     | 65   | 6.16E-20 | 1.73E-17 |
| L13a-mediated translational silencing of ceruloplasmin expression | 201   | 19.2     | 65   | 6.16E-20 | 1.73E-17 |
| Translation                                            | 249   | 23.8     | 73   | 1.63E-19 | 3.81E-17 |
| Nonsense mediated decay independent of the exon junction complex | 184   | 17.6     | 61   | 2.27E-19 | 4.54E-17 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 201   | 19.2     | 64   | 3.02E-19 | 5.30E-17 |
| Eukaryotic translation elongation                       | 186   | 17.8     | 61   | 4.19E-19 | 6.53E-17 |
| Nonsense mediated decay enhanced by the exon junction complex | 203   | 19.4     | 64   | 5.39E-19 | 6.73E-17 |
| Nonsense-mediated decay                                 | 203   | 19.4     | 64   | 5.39E-19 | 6.73E-17 |

| PANTHER biological processes                          | Total | Expected | Hits | p        | pFDR     |
|--------------------------------------------------------|-------|----------|------|----------|----------|
| Translation                                            | 315   | 21.2     | 93   | 3.74E-36 | 7.25E-34 |
| MRNA splicing, via spliceosome                         | 236   | 15.9     | 52   | 1.26E-14 | 8.12E-13 |
| RNA splicing                                           | 289   | 19.5     | 55   | 1.33E-12 | 6.44E-11 |
| RNA metabolic process                                  | 47    | 3.17     | 20   | 5.08E-12 | 1.97E-10 |
| Protein folding                                        | 157   | 10.6     | 37   | 1.09E-11 | 3.52E-10 |
| MRNA processing                                        | 370   | 24.9     | 61   | 4.62E-11 | 1.28E-09 |
| Rhythmic process                                       | 124   | 8.35     | 31   | 1.05E-10 | 2.43E-09 |
| Blood coagulation                                      | 193   | 13.0     | 40   | 1.13E-10 | 2.43E-09 |
| Cell-matrix adhesion                                   | 91    | 6.13     | 25   | 8.03E-10 | 1.56E-08 |

FDR: False Discovery Rate; UTR: untranslated region; GTP: Guanosine-triphosphate.
Figure 1. First order protein network showing the results of Markov Clustering (MCL) analysis: 1) a first immune cluster was centered around ALB (albumin), CRP (C-reactive protein), IL10 (interleukin 10), IL6 (interleukin 6), SELE (E-selectin), TGFB1 (transforming growth factor beta 1), TNF (tumor necrosis factor), and VCAM1 (vascular cellular adhesion molecule 1), and 2) a second hemostasis-fibrin clot cluster centered around F8 (coagulation factor VIII), FGB (beta-fibrinogen), PROC (protein C), PROS1 (protein S), VWF (von Willebrand Factor), and SERPINC1 (antithrombin).
Figure 2. Heatmap of enriched terms showing the top-20 functions that were overexpressed in the network of patients who died due to ischemic stroke (accumulative hypergeometric p-values).
Figure 3. Heatmap of enriched KEGG (Kyoto Encyclopedia of Genes and Genomes) terms showing the top-10 functions that were overexpressed in the first protein subnetwork of patients who died due to ischemic stroke (accumulative hypergeometric p-values).

TNF: tumor necrosis factor; IL: interleukin; NF-kappa B: nuclear factor kappa B; NOD: nucleotide-binding, and oligomerization domain.
Figure 4. Heatmap of enriched InterPro domains showing the top-10 functions that were overexpressed in the first protein subnetwork of patients who died due to ischemic stroke (accumulative hypergeometric p-values).
Figure 5. Heatmap of enriched Gene Ontology (GO) molecular functions that were overexpressed in the second protein subnetwork of patients who died due to ischemic stroke (accumulative hypergeometric p-values).

I-SMAD: inhibitory SMAD.
Figure 6. Heatmap of enriched InterPro domains showing the top-10 functions that were overexpressed in the second protein subnetwork of patients who died due to ischemic stroke (cumulative hypergeometric p-values).

VWA: von Willebrand factor type A; MAD: Mothers against Dpp (decapentaplegic); MH1: MAD 1 homology (N terminus); SMAD: Superfamily of Mothers against Dpp; EGF: Epithelial growth factor
**Figure 7.** First order protein network showing the results of Markov Clustering (MCL) analysis with 1) a first hemostasis-fibrin clot cluster (in red); and 2) a second immune cluster (green).